[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 328
1. Lee HL, Son BK, Lee OY, Jeon YC, Han DS, Sohn JH, Yoon BC, Choi HS, Hahm JS, Lee MH, Lee DH, Kee CS: [Abdominal obesity, insulin resistance, and the risk of colonic adenoma]. Korean J Gastroenterol; 2007 Mar;49(3):147-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abdominal obesity, insulin resistance, and the risk of colonic adenoma].
  • BACKGROUND/AIMS: Abdominal obesity and hyperinsulinemia or insulin resistance are of interest in connection with colon carcinogenesis.
  • We conducted a prospective case controlled study for the evaluation of relationship between abdominal obesity, insulin resistance, and colorectal adenoma.
  • METHODS: Fifty patients with colorectal adenoma and fifty healthy subjects were included in this study.
  • RESULTS: There were no differences in sex, serum insulin, FBS, HOMA-IR, TG, CROL between adenoma and control group.
  • Subjects with high BMI, WHR, percent body fat, and obesity were more likely to have colonic adenoma.
  • Multiple logistic regression analysis after adjusting confounding factors, had revealed that WHR was the most important independent risk factor for colon adenoma.
  • CONCLUSIONS: Abdominal obesity was most closely related to colonic adenoma.
  • However, insulin resistance was not related to colonic adenoma.
  • [MeSH-major] Abdominal Fat. Adenoma / etiology. Colonic Neoplasms / etiology. Insulin Resistance. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2007 Mar;49(3):192-5 [18172350.001]
  • (PMID = 18172342.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Kaneko R, Sato Y, An Y, Nakagawa M, Kusayanagi S, Kamisago S, Umeda T, Ogawa M, Munakata K, Mizuno K: Clinico-epidemiologic study of the metabolic syndrome and lifestyle factors associated with the risk of colon adenoma and adenocarcinoma. Asian Pac J Cancer Prev; 2010;11(4):975-83
MedlinePlus Health Information. consumer health - Metabolic Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-epidemiologic study of the metabolic syndrome and lifestyle factors associated with the risk of colon adenoma and adenocarcinoma.
  • Prevention is clearly important and the present study aimed to clarify risk factors and to promote colon cancer screening.
  • RESULTS: Low-grade adenoma was more frequent among the elderly and in men.
  • All of the men and 87.5% of the women with high-grade adenoma or adenocarcinoma were aged≥45 and≥50 years, respectively.
  • In women, a larger waist circumference (=80 cm) increased the odds ratio for colon adenoma or adenocarcinoma (colon tumors) by 1.033 (95% confidence index (CI), 1.001-1.066; p=0.040).
  • Metabolic syndrome significantly increased the odds ratio of colon tumors in men, but not in women.
  • Cigarette smoking, drinking alcohol, and increased physical activity were significant risk factors for colon tumors in men, with odds ratios of 1.001 (95% CI, 1.000-1.002; p=0.001), 1.001 (95% CI, 1.000-1.003; p=0.047), and 1.406 (95% CI 1.038-1.904; p=0.028), respectively.
  • CONCLUSIONS: Colon tumors have a high prevalence in the elderly.
  • A larger waist circumference in women and metabolic syndrome in both men and women elevate the risk of colon tumors.
  • In addition, smoking, drinking, and excessive physical activity are risk factors for adenoma and adenocarcinoma in men.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Metabolic Syndrome X / complications

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133610.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


3. Byun TJ, Han DS, Ahn SB, Cho HS, Eun CS, Jeon YC, Sohn JH, Oh YH: Pseudoinvasion in an adenomatous polyp of the colon mimicking invasive colon cancer. Gut Liver; 2009 Jun;3(2):130-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoinvasion in an adenomatous polyp of the colon mimicking invasive colon cancer.
  • Pseudoinvasion or pseudocarcinomatous invasion in an adenomatous polyp of the colon can be unfamiliar to an endoscopist.
  • Pseudoinvasion in an adenomatous polyp represents prolapse of the adenomatous epithelium into its stalk.
  • In most cases its morphology does not differ from of general adenomatous polyps, but in some cases it can morphologically mimic a malignant polyp with submucosal invasion due to mass-like lesioning of its stalk.
  • This makes it difficult for endoscopists to differentiate pseudoinvasion in an adenoma from an invasive carcinoma by conventional endoscopy; instead, endoscopic ultrasonography can provide useful information for differentiating these conditions.
  • We report on an 82-year-old man who presented with a large pedunculated polyp with a thick stalk in the sigmoid colon, which mimicked a submucosal invasive carcinoma.
  • The patient was diagnosed with pseudoinvasion in an adenomatous polyp after segmental resection of the sigmoid colon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1973 Jan;26(1):25-31 [4540378.001]
  • [Cites] Cancer. 1974 Jan;33(1):206-17 [4810096.001]
  • [Cites] Dis Colon Rectum. 1980 Nov-Dec;23(8):529-35 [7460689.001]
  • [Cites] Endoscopy. 2001 Aug;33(8):709-18 [11490390.001]
  • [Cites] Adv Anat Pathol. 2008 Jan;15(1):1-17 [18156808.001]
  • [Cites] Gastrointest Endosc. 2003 May;57(6):722 [12709708.001]
  • [Cites] Pathol Int. 2003 Sep;53(9):584-90 [14507314.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):206-15 [11812942.001]
  • (PMID = 20431736.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852693
  • [Keywords] NOTNLM ; Adenomatous polyps / EUS / Malignant polyp / Pseudoinvasion
  •  go-up   go-down


Advertisement
4. Castillo-Alcala F, Mans C, Bos AS, Taylor WM, Smith DA: Clinical and pathologic features of an adenomatous polyp of the colon in a domestic ferret (Mustela putorius furo). Can Vet J; 2010 Nov;51(11):1261-4
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic features of an adenomatous polyp of the colon in a domestic ferret (Mustela putorius furo).
  • A 6-year-old castrated male domestic ferret (Mustela putorius furo) with a 4-week history of intermittent diarrhea and straining during defecation had an intraluminal mass in the descending colon identified by abdominal ultrasound.
  • The histopathological diagnosis of the resected mass was an adenomatous polyp of the colon.
  • [MeSH-major] Adenomatous Polyps / veterinary. Colonic Polyps / veterinary. Ferrets

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Anim Hosp Assoc. 1997 Mar-Apr;33(2):156-60 [9111726.001]
  • [Cites] J Am Vet Med Assoc. 1998 May 1;212(9):1402-6 [9589126.001]
  • [Cites] Vet Surg. 2006 Jun;35(4):337-40 [16756613.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2551-7 [17167138.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):886-9 [11021873.001]
  • (PMID = 21286327.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2957035
  •  go-up   go-down


5. Murff HJ, Shrubsole MJ, Smalley WE, Wu H, Shyr Y, Ness RM, Zheng W: The interaction of age and hormone replacement therapy on colon adenoma risk. Cancer Detect Prev; 2007;31(2):161-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interaction of age and hormone replacement therapy on colon adenoma risk.
  • BACKGROUND: Several studies have identified a possible interaction between age and hormone replacement therapy on colon neoplasm risk.
  • RESULTS: There was a significant interaction between age and hormone replacement therapy use (P=0.03) with current estrogen users who were over 56 years of age having a reduced odds of colon adenoma (OR, 0.40; 95% CI, 0.16-0.98) when compared to never users.
  • Both older women who had used hormone replacement therapy for 3 or less years (OR, 0.07; 95% CI, 0.006-0.81) and those reporting greater than 10 years of use (OR, 0.27; 95% CI, 0.09-0.80) had a reduced adjusted odds for adenomas when compared to non-users.
  • CONCLUSIONS: Duration of use is not likely to explain the stronger association of hormone replacement therapy use with colon neoplasm in older women.

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):443-7 [10794491.001]
  • [Cites] Obstet Gynecol. 1999 May;93(5 Pt 2):880-8 [10912438.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):126-30 [11196149.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1799-805 [11734596.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):622-9 [12101109.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):546-52 [15066918.001]
  • [Cites] Lancet. 1970 Sep 12;2(7672):535-7 [4195202.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):359-66 [8080948.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 19;87(14):1067-71 [7616598.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):130-8 [9134236.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):146-58 [9134238.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):329-33 [9568789.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):653-9 [9718216.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):212-7 [10211498.001]
  • [Cites] Am J Med. 1999 May;106(5):574-82 [10335731.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1219-23 [15894675.001]
  • [Cites] Cancer Causes Control. 2005 Oct;16(8):965-73 [16132805.001]
  • (PMID = 17433566.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / K07 CA114029; United States / NCI NIH HHS / CA / R01 CA097386-01; United States / NCI NIH HHS / CA / K07 CA114029-01A2; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / P50 CA095103-01; United States / NCI NIH HHS / CA / CA95103; United States / NCI NIH HHS / CA / CA097386-01; United States / NCI NIH HHS / CA / R01 CA97386
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS24075; NLM/ PMC1949417
  •  go-up   go-down


6. Rubio CA: Luminal histological outline and colonic adenoma phenotypes. Anticancer Res; 2007 Sep-Oct;27(5B):3555-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luminal histological outline and colonic adenoma phenotypes.
  • BACKGROUND: The luminal appearance of histological sections from colonic adenomas exhibits two different profiles: one regularly smooth and the other asymmetrically lumpy.
  • MATERIALS AND METHODS: For this purpose, the largest section of 107 consecutive endoscopically removed colonic adenomas was digitalized using an Epson Perfection 4990 PHOTO device.
  • RESULTS: Asymmetrically lumpy profiles were found in 96% (22/23) of the sections from adenomas measuring > or =15 mm, in 72% (39/54) of those having villous, mixed serrated or microtubular configurations and in 89% (24/27) showing carcinoma according to the Vienna classification.
  • CONCLUSION: The asymmetrically lumpy profile of sections from endoscopically excised colonic adenomas correlated with the size of the sections, the histological phenotype and the degree of neoplastic transformation.
  • Studies have been initiated to clinically explore whether the luminal configuration of colonic adenomas can be of help in predicting, before endoscopical removal, accepted histological parameters.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972517.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Kim SE, Shim KN, Jung SA, Yoo K, Moon IH: An association between obesity and the prevalence of colonic adenoma according to age and gender. J Gastroenterol; 2007 Aug;42(8):616-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An association between obesity and the prevalence of colonic adenoma according to age and gender.
  • BACKGROUND: Epidemiologic data on obesity as a risk factor for colonic adenoma with respect to gender have not yet been confirmed.
  • Here, we aimed to compare the prevalence of colonic adenoma and of advanced polyps in age-stratified men and women at baseline, to examine the role of body mass index (BMI) on colonic adenoma risk according to age and gender, and to examine the influence of menopausal status.
  • BMI was assessed, and histology, size, and location of the adenoma were examined for each patient.
  • RESULTS: A significant increase in the prevalence of colonic adenoma and of advanced polyps was found to occur with age (P for trend < 0.01).
  • The prevalences of adenoma and advanced polyps were higher in men in most age groups (P < 0.01), but no significant difference in prevalences was observed between genderes in patients 70 years of age or older.
  • Moreover, a positive association between BMI and the prevalence of colonic adenoma and advanced polyps was shown in relatively young individuals of both gender (men in their thirties, P < 0.05; women in their forties, P < 0.05), and premenopausal women according to hormonal status (P = 0.01).
  • CONCLUSIONS: Our data suggest that obesity increases the risk of colonic adenoma in relatively young people and in premenopausal women subject to estrogen effects.
  • [MeSH-major] Adenoma / epidemiology. Colonic Neoplasms / epidemiology. Obesity / complications
  • [MeSH-minor] Adult. Age Factors. Aged. Biopsy. Body Mass Index. Colonic Polyps / epidemiology. Colonic Polyps / etiology. Colonic Polyps / pathology. Colonoscopy. Female. Humans. Korea / epidemiology. Male. Menopause. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701124.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Kuefner MA, Schwelberger HG, Hahn EG, Raithel M: Decreased histamine catabolism in the colonic mucosa of patients with colonic adenoma. Dig Dis Sci; 2008 Feb;53(2):436-42
Hazardous Substances Data Bank. HISTAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased histamine catabolism in the colonic mucosa of patients with colonic adenoma.
  • INTRODUCTION: Alterations in mucosal histamine degradation play an important role in various gastrotinestinal diseases including colonic adenoma.
  • METHODS: About 94 colonic biopsies were endoscopically obtained from 23 patients suffering from colonic adenoma and 26 biopsies from six healthy individuals.
  • RESULTS: In adenoma patients DAO activities were slightly and HNMT activities were significantly decreased in normal mucosa compared to controls.
  • Activities of both enzymes were significantly lower in adenoma tissue than in healthy mucosa in the same patients.
  • Histamine concentrations were elevated in adenoma patients.
  • CONCLUSIONS: Histamine catabolism is decreased in the colonic mucosa of patients with colonic adenoma.
  • [MeSH-major] Adenoma / metabolism. Colonic Neoplasms / metabolism. Histamine / metabolism. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma, Villous / metabolism. Adult. Aged. Amine Oxidase (Copper-Containing) / metabolism. Female. Histamine N-Methyltransferase / metabolism. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562176.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 820484N8I3 / Histamine; EC 1.4.3.21 / Amine Oxidase (Copper-Containing); EC 2.1.1.8 / Histamine N-Methyltransferase
  •  go-up   go-down


9. Pusztaszeri M, Bouzourene H: Invasive carcinoma arising from a colonic adenoma with clear cell change. Hum Pathol; 2008 Sep;39(9):1402-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive carcinoma arising from a colonic adenoma with clear cell change.
  • Clear cell change (CCC) in colonic adenoma is rare, and its biological and clinical significance remains unknown.
  • Malignant progression of an adenoma with CCC has seldom been reported.
  • We report a case of a sigmoid adenoma with multiple foci of CCC associated with high-grade dysplasia and invasive carcinoma in a 62-year-old patient.
  • We evaluated the histochemical and immunohistochemical characteristics of each component of the adenoma.
  • In contrast to other parts of the adenoma, p53 was strongly and diffusely overexpressed in the areas of CCC, high-grade dysplasia, and carcinoma.
  • The MIB-1 labeling index was also significantly higher in these components than in other parts of the adenoma.
  • In conclusion, our findings suggest that CCC in adenoma may be associated with malignant progression of the adenoma.
  • Hence, for practical purposes, we recommend considering CCC in colonic adenomas as a high-grade dysplasia equivalent and following up the patient accordingly.
  • [MeSH-major] Adenoma / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602669.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


10. Pantanowitz L: Colonic adenoma with squamous metaplasia. Int J Surg Pathol; 2009 Aug;17(4):340-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenoma with squamous metaplasia.
  • Squamous metaplasia arising within colon adenomas is a rare occurrence, with a 0.4% incidence noted predominantly in elderly males.
  • A case of squamous metaplasia arising in a tubulovillous adenoma of the cecum, associated with adenocarcinoma, is described.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701516.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


11. Pucciarelli S, Enzo M, Agostini M, Pizzini S, Del Bianco P, Lonardi S, Friso M, Mescoli C, Urso E, Nitti D: Cell-free circulating DNA as a promising marker of colorectal cancer detection and progression. J Clin Oncol; 2009 May 20;27(15_suppl):11059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11059 Background: Since the pathologic stage is the most powerful prognostic factor for colorectal cancer (CRC), there is a strong need of non-invasive methods for early detection.
  • METHODS: cfDNA was extracted from plasma samples from 136 patients with primary CRC at different stages [median age 64 yrs; male/female 78/58; stages I-II, 61; stages III-IV, 75], and from 24 patients with adenomas [median age 67 yrs; male/female 17/7)] and from 55 clean-colon healthy subjects [median age 56 yrs; male/female 13/43).
  • The levels of cfDNA (ALU-115, ALU-247) of CRC patients (stages I-II and stages III-IV) were compared with those of healthy subjects and patients with adenoma.
  • RESULTS: The median concentrations of total cfDNA (ALU115) in the plasma samples from patients with stages III-IV and stages I-II CRC, adenoma and normal controls were 52,4, 11.9; 1.9, and 1.7 ng/ml, respectively (p<.0001).
  • With a cut-off of 4.86 ng/ml, total DNA (ALU115) showed a sensitivity of 78.52 (95% CI 70.6-85.1) and a specificity of 86.08 (95% CI 76.4-92.8) in distinguishing patients with CRC from non-CRC [AUC: 0.860 (95% CI 0.81-0,90), p-value=.0001].
  • With a cut-off of 3.04, cfDNA tumor-related (ALU247) showed a sensitivity of 77.94 (95% CI 70.0-84.6) and a specificity of 82.28 (95% CI 72.1-90.0) in distinguishing patients with CRC from non-CRC [AUC: 0.864 (95% CI 0.81-0,91), p-value=.0001].
  • CONCLUSIONS: Both ALU115 and ALU 247 fragments of circulating cfDNA seem promising non-invasive molecular markers of detection and progression of CRC.
  • The findings of the current study require to be confirmed on larger cohorts of patients with CRC and colonic adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963165.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Shin JE, Jung SA, Kim SE, Joo YH, Shim KN, Kim TH, Yoo K, Moon IH: [Expression of MMP-2, HIF-1alpha and VEGF in colon adenoma and colon cancer]. Korean J Gastroenterol; 2007 Jul;50(1):9-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of MMP-2, HIF-1alpha and VEGF in colon adenoma and colon cancer].
  • BACKGROUND/AIMS: This study was aimed to investigate the expression of matrix metalloproteinase-2 (MMP-2), hypoxia-inducible factor (HIF)-1alpha, and vascular endothelial growth factor (VEGF) in colonic adenoma-carcinoma sequence.
  • METHODS: Thirty-two tissue samples of colon adenoma, 11 of early colon cancer and 36 of advanced colon cancer were collected by colonoscopic biopsy.
  • Normal colonic tissues were also collected from the same subjects.
  • RESULTS: The expression level of MMP-2 mRNA showed a progressive increase in the advance of the colorectal adenoma-carcinoma sequence (p<0.05).
  • In colon cancer tissues, the expression level of MMP-2 mRNA showed an increasing trend according to differentiation, lymphatic invasion and Dukes' stage (p<0.05).
  • The mRNA expression levels of HIF-1alpha and VEGF were greater in tissues of early and advanced colon cancer compared with colon adenoma (p<0.05; p<0.001).
  • CONCLUSIONS: MMP-2, HIF-1alpha, and VEGF may be useful in detecting early carcinogenesis and progression of colon cancer.
  • [MeSH-major] Adenoma / metabolism. Colonic Neoplasms / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Matrix Metalloproteinase 2 / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172354.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


13. Harada K, Higaki S, Amano A, Hashimoto K, Hashimoto S, Gondo T, Sakaida I: A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon. Oncol Rep; 2007 Jun;17(6):1353-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon.
  • The histogenesis of depressed adenoma of the colon has not been sufficiently investigated.
  • Pericryptal myofibroblasts are stromal cells expressing smooth muscle actin, and are involved in the differentiation and multiplication of epithelial cells in the colonic epithelium.
  • COX-2 has been reported to be involved in the development of colon adenoma.
  • We studied the histogenesis of depressed adenoma of the colon by examining the relationship between the presence of pericryptal myofibroblasts and COX-2 expression.
  • Twenty-one depressed adenomas of the colon that had been resected endoscopically between June 1998 and May 2003 (mild-moderate atypia; mean diameter, 6.7 mm) and 23 elevated adenomas that had been resected endoscopically in 2003 (mild-moderate atypia; mean diameter, 11.7 mm), were studied.
  • Eighteen (78.3%) of the 23 elevated adenomas and six (28.6%) of the 21 depressed adenomas were positive for pericryptal myofibroblasts immunohistochemically, showing a significant difference (P<0.001).
  • Seventeen elevated adenomas (73.9%) and eight depressed adenomas (38.1%) were positive for COX-2 expression (P=0.016).
  • The histogenesis of depressed adenomas differs from that of elevated adenomas.
  • Our results suggest that a low number of pericryptal myofibroblasts and a low COX-2 expression are associated with depressed adenomas.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Cyclooxygenase 2 / metabolism. Fibroblasts / pathology. Membrane Proteins / metabolism. Myoblasts / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487390.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


14. Tanaka S, Tatsuguchi A, Futagami S, Gudis K, Wada K, Seo T, Mitsui K, Yonezawa M, Nagata K, Fujimori S, Tsukui T, Kishida T, Sakamoto C: Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut; 2006 Jan;55(1):54-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma.
  • BACKGROUND AND AIMS: Cyclooxygenase 2 (COX-2) expression in subepithelial macrophages of colorectal adenoma has been suggested as the first in a series of steps leading to colorectal tumorigenesis.
  • We tested the hypothesis that chemokines released from human colorectal adenoma epithelium might be involved in COX-2 expression in macrophages of the lamina propria.
  • METHODS: Endoscopic samples of sporadic colorectal adenomas were tested by enzyme linked immunosorbent assay for chemokines involved in macrophage chemotaxis.
  • Localisation of adenoma macrophage chemoattractant protein 1 (MCP-1) and COX-2 were determined by immunohistochemistry.
  • RESULTS: MCP-1 levels were markedly higher in adenoma with mild-moderate dysplasia (129.7 (19.9) pg/mg protein) and severe dysplasia (227.9 (35.4) pg/mg protein) than in normal colonic mucosa (55.8 (4.2) pg/mg protein).
  • Other chemokine levels, macrophage inflammatory proteins (MIP)-1alpha and MIP-1beta, and the chemokine regulated on activation of normal T cell expressed and secreted (RANTES) did not vary significantly between adenoma and normal mucosa.
  • MCP-1 levels in both adenoma and normal colonic mucosa increased significantly three hours after tissue cultivation in vitro.
  • MCP-1 immunoreactivity was restricted to the adenoma epithelium, with no reactivity seen in adjacent normal epithelial cells.
  • Addition of exogenous PGE(2) reversed this inhibitory effect on VEGF release, suggesting that MCP-1 in adenoma epithelial cells might be involved in COX-2 expression and subsequent macrophage activation.
  • CONCLUSIONS: MCP-1 in colorectal adenoma epithelial cells might be involved in macrophage migration and COX-2 expression, leading to the subsequent development of colonic adenoma.
  • [MeSH-major] Adenoma / metabolism. Chemokine CCL2 / metabolism. Colorectal Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. Macrophages / enzymology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):751-8 [10544003.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):470-5 [10508481.001]
  • [Cites] J Pharmacol Exp Ther. 2000 May;293(2):539-44 [10773026.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Jun;19(2):219-23 [10965822.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Nov;295(2):802-9 [11046121.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1733-40 [11245490.001]
  • [Cites] Acta Oncol. 2001;40(5):622-8 [11669335.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1339-47 [11729113.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1669-75 [11912138.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):220-4 [12397639.001]
  • [Cites] J Pathol. 2002 Dec;198(4):435-41 [12434412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2736-41 [12598658.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):773-8 [12632067.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):328-36 [12891533.001]
  • [Cites] Cancer Causes Control. 2003 Jun;14(5):403-11 [12946034.001]
  • [Cites] Gut. 2003 Oct;52(10):1448-56 [12970138.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1317-22 [14532971.001]
  • [Cites] Ann Intern Med. 2004 Feb 3;140(3):157-66 [14757613.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):488-95 [15116331.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G444-51 [15246970.001]
  • [Cites] J Surg Oncol. 1983 Sep;24(1):83-7 [6887943.001]
  • [Cites] Am J Surg. 1989 Jan;157(1):175-9 [2535920.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4482-6 [7753829.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5769-76 [7499865.001]
  • [Cites] Eur J Immunol. 1995 Dec;25(12):3482-8 [8566041.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4625-9 [8840975.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):387-97 [9024292.001]
  • [Cites] Arch Intern Med. 1999 Jan 25;159(2):161-6 [9927099.001]
  • [Cites] Acta Obstet Gynecol Scand. 1999 Mar;78(3):240-4 [10078587.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1399-405 [10188882.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1107-13 [10353745.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):545-53 [10666384.001]
  • (PMID = 16085694.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Chemokine CCL2; 0 / Chemokines; 0 / Cyclooxygenase Inhibitors; 0 / Neoplasm Proteins; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1856393
  •  go-up   go-down


15. Egan JB, Thompson PA, Ashbeck EL, Conti DV, Duggan D, Hibler E, Jurutka PW, Leroy EC, Martínez ME, Mount D, Jacobs ET: Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. Cancer Res; 2010 Feb 15;70(4):1496-504
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence.
  • No gene-level associations were observed for VDR, nor was any single SNP in VDR related to any metachronous adenoma after correction for multiple comparisons.
  • Haplotypes within linkage blocks of RXRA support an approximately 30% reduction in odds of metachronous neoplasia arising in the proximal colon among carriers of specific haplotypes, which was strongest (OR(proximal), 0.67; 95% CI, 0.52-0.86) for carriers of a CGGGCA haplotype (rs1805352, rs3132297, rs3132296, rs3118529, rs3118536, and rs7861779).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2006 Nov;27(11):1129-34 [16937379.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1706-16 [17087956.001]
  • [Cites] Genet Epidemiol. 2007 Jul;31(5):383-95 [17410554.001]
  • [Cites] J Clin Gastroenterol. 2007 Sep;41(8):731-46 [17700421.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):793-810 [17906642.001]
  • [Cites] Gut. 2007 Nov;56(11):1557-63 [17604322.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602 [17971526.001]
  • [Cites] PLoS One. 2008;3(1):e1483 [18213391.001]
  • [Cites] Nutr Cancer. 2008;60(1):97-108 [18444141.001]
  • [Cites] Cell Mol Life Sci. 2008 May;65(10):1523-43 [18278436.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):586-93 [18470879.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):944-8 [18375961.001]
  • [Cites] Nutr Rev. 2008 Oct;66(10 Suppl 2):S98-112 [18844852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):2958-69 [18990737.001]
  • [Cites] Carcinogenesis. 2009 May;30(5):769-76 [19255064.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1170-80 [19403841.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2304-12 [10786699.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):3931-9 [11089522.001]
  • [Cites] J Cell Biol. 2001 Jul 23;154(2):369-87 [11470825.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):869-74 [11489753.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):607-14 [11552708.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1267-74 [11751444.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25313-22 [12000762.001]
  • [Cites] Exp Hematol. 2003 Jun;31(6):488-94 [12829024.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29954-62 [12771132.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7799-806 [14633706.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1502-8 [15342452.001]
  • [Cites] Int J Epidemiol. 1980 Sep;9(3):227-31 [7440046.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Endocrinology. 1994 Apr;134(4):1710-7 [8137734.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):623-32 [8564982.001]
  • [Cites] J Endocrinol. 1997 Sep;154 Suppl:S57-73 [9379138.001]
  • [Cites] J Bone Miner Res. 1998 Mar;13(3):325-49 [9525333.001]
  • [Cites] Hum Genet. 1998 Oct;103(4):462-9 [9856491.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):846-53 [15928305.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):144-51 [16004730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2061-3 [16172209.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Endocr Rev. 2005 Dec;26(7):898-915 [16126938.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] Am J Hum Genet. 2006 Apr;78(4):629-44 [16532393.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Anticancer Res. 2009 Sep;29(9):3511-36 [19667145.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1158-68 [17966093.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):1030-4 [16936639.001]
  • (PMID = 20145122.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA106269; United States / NCI NIH HHS / CA / CA023074-22S1; United States / NCI NIH HHS / CA / P50 CA095060-01; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / K07CA106269; United States / NCI NIH HHS / CA / CA95060; United States / NCI NIH HHS / CA / CA77145; United States / NCI NIH HHS / CA / P01 CA041108; United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA095060-01; United States / NCI NIH HHS / CA / P50 CA095060; United States / NCI NIH HHS / CA / R01 CA123065; United States / NCI NIH HHS / CA / K07 CA106269-01A1; United States / NCI NIH HHS / CA / P30 CA023074-22S1; United States / NCI NIH HHS / CA / P01 CA041108-13; United States / NCI NIH HHS / CA / P01CA41108; United States / NCI NIH HHS / CA / CA041108-13; United States / NCI NIH HHS / CA / CA106269-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Retinoid X Receptor alpha
  • [Other-IDs] NLM/ NIHMS262521; NLM/ PMC3019606
  •  go-up   go-down


16. Veeriah S, Hofmann T, Glei M, Dietrich H, Will F, Schreier P, Knaup B, Pool-Zobel BL: Apple polyphenols and products formed in the gut differently inhibit survival of human cell lines derived from colon adenoma (LT97) and carcinoma (HT29). J Agric Food Chem; 2007 Apr 18;55(8):2892-900

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apple polyphenols and products formed in the gut differently inhibit survival of human cell lines derived from colon adenoma (LT97) and carcinoma (HT29).
  • Here, apple polyphenols were studied for effects on the survival of colon adenoma (LT97) and carcinoma-derived (HT29) cell lines.
  • [MeSH-major] Cell Survival / drug effects. Colonic Neoplasms / pathology. Fermentation. Flavonoids / pharmacology. Fruit / chemistry. Malus / chemistry. Phenols / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378580.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Phenols; 0 / Plant Extracts; 0 / Polyphenols
  •  go-up   go-down


17. Wei HJ, Guo ZY, Xie SS, He BH, Li LB, Chen XM, Wu GY, Lu JJ: [Colon adenoma detection using Kubelka-Munk spectral function of DNA and protein bands]. Guang Pu Xue Yu Guang Pu Fen Xi; 2009 Jun;29(6):1473-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon adenoma detection using Kubelka-Munk spectral function of DNA and protein bands].
  • Differential diagnosis of human colon adenoma was studied using the Kubelka-Munk spectral function of the DNA and protein absorption bands at 260 and 280 nm in vitro.
  • The results of measurement showed that for the spectral range from 590 to 1 064 nm pathological changes of colon epithelial tissues were induced so that there were significant differences in the averaged values of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log [f(r infinity)] of the DNA absorption bands at 260 nm between normal and adenomatous colon epithelial tissues, and the differences were 218% (p < 0.05) and 68.5% (p < 0.05) respectively.
  • Pathological changes of colon epithelial tissues were induced so that there were significant differences in the averaged values of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log [f(r infinity)] of the protein absorption bands at 280 nm between normal and adenomatous colon epithelial tissues, and the differences were 208% (p < 0.05) and 59.0% (p < 0.05) respectively.
  • Pathological changes of colon epithelial tissues were induced so that there were significant differences in the averaged values of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log [f(r infinity)] of the beta-carotene absorption bands at 480 nm between normal and adenomatous colon epithelial tissues, and the differences were 41.7% (p < 0.05) and 32.9% (p < 0.05) respectively.
  • Obviously, pathological changes of colon epithelial tissues were induced so that there were significant changes in the contents of the DNA, protein and beta-carotene of colon epithelial tissues.
  • The conclusion can be applied to rapid, low-cost and noninvasive optical biopsy of colon adenoma, and provides a useful reference.
  • [MeSH-major] Adenoma / diagnosis. Colonic Neoplasms / diagnosis. DNA / chemistry. Proteins / chemistry. Spectrum Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810511.001).
  • [ISSN] 1000-0593
  • [Journal-full-title] Guang pu xue yu guang pu fen xi = Guang pu
  • [ISO-abbreviation] Guang Pu Xue Yu Guang Pu Fen Xi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteins; 9007-49-2 / DNA
  •  go-up   go-down


18. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • As proliferation is essential for progression from normal cells to tumor, certain markers specific to proliferating cells may permit detection of premalignant lesions.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


19. Ji JH, Park BJ, Park YS, Hwang JH, Chung SH, Kim N, Lee DH, Jung HC, Song IS: [Clinicopathologic study of colorectal polyps and obesity in Korean adult]. Korean J Gastroenterol; 2007 Jan;49(1):10-6
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of colorectal polyps and obesity in Korean adult].
  • Numerous epidemiologic studies have shown a positive association between obesity and colorectal polyps.
  • There are few studies investigating the association between colorectal adenomatous polyps and body fat composition in Korea.
  • We tried to examine the relationship between body fatness and colorectal adenomatous polyps in health check-up subjects in Korea.
  • METHODS: Six thousand seven hundred and six routine health check-up subjects, who visited our hospital between March 2002 and April 2005 and underwent distal colon examimation with sigmoidoscopy, were enrolled in this study.
  • Among them, colonoscopy was done in 860 patients to evaluate the entire colon.
  • We tried to reveal the relationship between body mass index (BMI) and size, location, number and histopathological type of polyps.
  • RESULTS: The mean value of BMI in total polyp-free group (23.8+/-2.9) was not different from that of the polyp group (24.5+/-2.8, p=0.09).
  • The frequency of rectosigmoid polyps in obese patients (20.4%) was higher than that in non-obese patients (16.0%, p<0.05).
  • The frequency of adenomatous polyp was not different between obese and non-obese group.
  • Number of polyps (> or=4) correlated well with obesity.
  • Moreover, age and triglyceride level in patients with colonic adenoma were significantly higher than in patients without colonic adenom.
  • CONCLUSIONS: This study shows that obesity is not associated with colonic adenomatous polyp in Korean population.
  • However, we observed that obesity may be associated with rectosigmoid colon polyps.
  • Furthermore, age and triglyceride level might be the risk factors of colonic adenomatous polyps in Korean population.
  • [MeSH-major] Adenomatous Polyps / complications. Colonic Neoplasms / complications. Obesity / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Body Mass Index. Colonic Polyps / complications. Colonic Polyps / epidemiology. Colonic Polyps / pathology. Comorbidity. Female. Humans. Korea. Male. Middle Aged. Retrospective Studies. Sigmoidoscopy

  • Genetic Alliance. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167428.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


20. Bergheim I, Bode C, Parlesak A: Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gastroenterol; 2005;5:34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma.
  • To estimate the role of cytochrome P450 in carcinogenesis of the colon, expression patterns and protein levels of four representative CYPs (CYP2C, CYP2E1, CYP3A4 and CYP3A5) were determined in colon mucosa of normal and adenomatous colonic tissue of patients with adenomas and disease-free controls.
  • METHODS: Expression of CYP2C, CYP2E1, CYP3A4, and CYP3A5 in colon mucosa of normal and adenomatous colonic tissue of patients with adenoma and disease-free controls was determined by RT-PCR.
  • RESULTS: With the exception of CYP3A5, expression of CYP mRNA was similar among groups and tissues (e.g. normal colon mucosa and adenoma).
  • CYP3A5 mRNA expression was significantly higher in adenoma in comparison to normal tissue of patients with adenoma (approximately 48%).
  • When comparing protein concentrations of CYPs measured in adenomas with neighboring normal colonic mucosa no differences were found.
  • However, in normal tissue of patients with adenomas, protein levels of CYP2C8, CYP3A4 and CYP3A5, but not that of CYP2E1, were significantly lower than in biopsies obtained from disease-free controls.
  • Specifically, in normal colonic mucosa of patients protein concentrations of CYP2C8, CYP3A4, and CYP3A5 were approximately 86%, approximately 69%, and approximately 54%, respectively, lower than in disease-free controls.
  • CYP2C8, CYP3A4 and CYP3A5) in colon mucosa might contribute to the development of neoplasia in the colon.
  • [MeSH-major] Adenoma / enzymology. Colon / enzymology. Colonic Neoplasms / enzymology. Cytochrome P-450 CYP2E1 / metabolism. Cytochrome P-450 Enzyme System / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 2000 Apr 1;376(1):180-90 [10729204.001]
  • [Cites] Virchows Arch. 1999 May;434(5):401-11 [10389623.001]
  • [Cites] Arch Biochem Biophys. 2002 Feb 1;398(1):109-17 [11811955.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Nov 15;298(5):687-92 [12419308.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:149-73 [12171978.001]
  • [Cites] J Pharm Pharmacol. 2003 Jan;55(1):59-66 [12625868.001]
  • [Cites] Front Biosci. 2004 May 1;9:1967-76 [14977602.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Gut. 1991 Apr;32(4):408-12 [1902809.001]
  • [Cites] Carcinogenesis. 1991 May;12(5):905-9 [2029756.001]
  • [Cites] Mol Cell Biochem. 1991 Mar 27;102(1):61-9 [2052000.001]
  • [Cites] Crit Rev Toxicol. 1991;21(6):407-22 [1801846.001]
  • [Cites] J Biol Chem. 1992 Aug 5;267(22):15765-9 [1639811.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6567-75 [1423302.001]
  • [Cites] Gut. 1993 Sep;34(9):1234-9 [8406161.001]
  • [Cites] Mutat Res. 1993 Nov;290(1):27-33 [7694095.001]
  • [Cites] Anal Biochem. 1993 Sep;213(2):414-21 [8238918.001]
  • [Cites] Biochem Pharmacol. 1994 Jul 5;48(1):59-64 [8043031.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(6):497-502 [7923560.001]
  • [Cites] Pharmacogenetics. 1994 Oct;4(5):247-59 [7894497.001]
  • [Cites] Biochem Biophys Res Commun. 1995 May 16;210(2):350-5 [7755610.001]
  • [Cites] Biochem Pharmacol. 1996 Jan 12;51(1):61-9 [8534269.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):207-12 [8717162.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Feb 3;231(1):203-5 [9070249.001]
  • [Cites] Drug Metab Dispos. 1999 Jul;27(7):804-9 [10383924.001]
  • [Cites] Curr Drug Metab. 2000 Sep;1(2):107-32 [11465078.001]
  • (PMID = 16281975.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / cytochrome P-450 CYP2C subfamily; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / CYP3A protein, human; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  • [Other-IDs] NLM/ PMC1310537
  •  go-up   go-down


21. Kim Y, Kim Y, Lee S: An association between colonic adenoma and abdominal obesity: a cross-sectional study. BMC Gastroenterol; 2009;9:4
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An association between colonic adenoma and abdominal obesity: a cross-sectional study.
  • BACKGROUND: Colorectal adenoma is a precursor lesion of colorectal cancer and thus, it is an important target for preventing colorectal cancer.
  • Only a few studies suggest an association between colorectal adenoma and obesity, but results show considerable heterogeneity.
  • In this study, we investigated the association between colorectal adenoma and waist circumference.
  • METHODS: 165 adenoma cases and 365 polyp-free controls with a normal colon were compared in this cross-sectional study.
  • And smokers and men were more prevalent among cases than controls.Among the abdominal obese subjects, 45.6% had 1 or more adenoma, and 9.0% of these had advanced adenoma, whereas among subjects with a normal waist circumference, only 25.7% had 1 or more adenomas.
  • The prevalence of adenoma was higher among abdominal obese group (P < 0.05).
  • Logistic regression analysis showed that abdominal obesity was associated with an increased risk of colorectal adenoma (OR, 2.74; 95% CI, 1.66~4.51 in men, OR, 2.58; 95% CI, 1.08~6.12 in women).
  • While BMI was found to be weekly associated with the risk of adenoma among men at the highest BMI levels.
  • However, BMI was not associated with the risk for adenoma after adjusting for waist circumference.
  • CONCLUSION: Our data suggest that abdominal obesity is associated with an increased risk of colorectal adenoma.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):805-11 [10543250.001]
  • [Cites] Gut. 2008 Aug;57(8):1166-76 [18628378.001]
  • [Cites] Nutr Cancer. 2000;37(1):19-26 [10965515.001]
  • [Cites] Circulation. 2000 Sep 12;102(11):1296-301 [10982546.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Am J Epidemiol. 2000 Nov 1;152(9):847-54 [11085396.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):346-9 [11487263.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] J Endocrinol Invest. 2002 Nov;25(10):876-83 [12508950.001]
  • [Cites] Am J Prev Med. 2003 Feb;24(2):170-6 [12568823.001]
  • [Cites] Arch Intern Med. 2003 Feb 10;163(3):309-14 [12578511.001]
  • [Cites] Am J Epidemiol. 2003 Sep 1;158(5):424-31 [12936897.001]
  • [Cites] J Clin Invest. 1983 Sep;72(3):1150-62 [6350364.001]
  • [Cites] Jpn J Cancer Res. 1989 Jan;80(1):51-8 [2540132.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):372-5 [2406206.001]
  • [Cites] Cancer Causes Control. 1991 Mar;2(2):117-24 [1873436.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1101-8 [1312970.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Jpn J Cancer Res. 1994 May;85(5):479-84 [8014105.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):327-34 [7847643.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):161-5 [9754646.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 [10203281.001]
  • [Cites] Am J Epidemiol. 1999 Oct 15;150(8):869-77 [10522658.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3642-6 [15897559.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Jan;75(1):72-80 [16735075.001]
  • [Cites] Swiss Med Wkly. 2007 Jan 27;137(3-4):50-6 [17299670.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2208-25 [17498513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2533-47 [18086756.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1160-5 [18546286.001]
  • [Cites] Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S53-60 [10772419.001]
  • (PMID = 19144203.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2635368
  •  go-up   go-down


22. Friedland S, Soetikno R, Carlisle M, Taur A, Kaltenbach T, Segall G: 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer. Gastrointest Endosc; 2005 Mar;61(3):395-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer.
  • BACKGROUND: 18-Fluorodeoxyglucose positron emission tomography (PET) is used clinically to detect recurrent colon cancer after surgical resection, but the sensitivity of PET for premalignant colon lesions and early stage colon cancer is not well defined.
  • METHODS: In a prospective study, 45 patients with a total of 58 colonic neoplasms, including premalignant polyps, premalignant, flat lesions, and early stage cancers, were evaluated by PET.
  • CONCLUSIONS: PET has limited sensitivity for flat, premalignant lesions; protruded, premalignant lesions smaller than 3 cm; and colon cancers smaller than 2 cm.
  • [MeSH-major] Adenoma / diagnostic imaging. Colonic Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Precancerous Conditions / diagnostic imaging. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15758910.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Schindler AE: Long-term use of progestogens: colon adenoma and colon carcinoma. Gynecol Endocrinol; 2007 Oct;23 Suppl 1:42-4
MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term use of progestogens: colon adenoma and colon carcinoma.
  • Colon cancer is the second most common cancer in women in the Western world and there is a trend towards an increasing risk.
  • Colon adenoma is a potential precursor for colon cancer.
  • Adenoma and carcinoma of the colon seem to be influenced by estrogens and progesterone/progestins.
  • This is related to the presence of estrogen and progesterone receptors, with apparently higher concentrations in colon cancers than in adenomas.
  • Epidemiological data and the finding of a significant reduction in colon cancer risk related to hormone replacement therapy (HRT), and in particular the length of HRT intake, indicate that progesterone/progestins have a preventive effect.
  • Furthermore, the recurrence rate of adenoma appears to be reduced, and the survival of colon cancer patients improved, with HRT; such effects have not been documented with ERT.
  • [MeSH-major] Adenoma / prevention & control. Carcinoma / prevention & control. Colonic Neoplasms / prevention & control. Hormone Replacement Therapy. Progestins / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943538.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins
  • [Number-of-references] 22
  •  go-up   go-down


24. Hazra A, Fuchs CS, Chan AT, Giovannucci EL, Hunter DJ: Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk. Cancer Causes Control; 2008 Nov;19(9):975-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk.
  • We evaluated the association of a polymorphism in TCF7L2 (RS12255372) in the WNT signaling pathway, which previously has been strongly associated with risk of Type II Diabetes, with colorectal cancer (CRC) and adenoma in the prospective Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts.
  • Hyperinsulinemia may be related to the risk of colon adenoma and cancer, therefore this variant associated with reduced insulin secretion would be predicted to be inversely associated with colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Jul 27;25(32):4441-8 [16547505.001]
  • [Cites] N Engl J Med. 2006 Jul 20;355(3):241-50 [16855264.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2645-8 [16936216.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2649-53 [16936217.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2654-9 [16936218.001]
  • [Cites] Diabetes. 2006 Oct;55(10):2890-5 [17003358.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] BMC Cancer. 2006;6:268 [17109766.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2408-17 [17164363.001]
  • [Cites] Diabetologia. 2007 Jan;50(1):5-7 [17102948.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3872-9 [10919662.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Curr Biol. 1998 May 7;8(10):573-81 [9601641.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Genet Anal. 1999 Feb;14(5-6):143-9 [10084106.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4213-5 [10485457.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):379-86 [10530607.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1457-64 [15525634.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):850-5 [15824155.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):863-70 [15824157.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):320-3 [16415884.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1830-7 [16410309.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):750-5 [16614119.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2640-4 [16936215.001]
  • (PMID = 18478343.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / T-32 CA 09001-30; United States / NCI NIH HHS / CA / K07 CA107412; United States / NCI NIH HHS / CA / CA70817; United States / NCI NIH HHS / CA / CA55075; United States / NCI NIH HHS / CA / CA107412-03; United States / NCI NIH HHS / CA / K07 CA107412-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Transcription Factor 7-Like 2 Protein
  • [Other-IDs] NLM/ NIHMS124556; NLM/ PMC2719293
  •  go-up   go-down


25. Fujiya M, Moriichi K, Saitoh Y, Watari J, Kohgo Y: Endoscopic piecemeal resection is a practical option to cure colorectal tumors. Dig Endosc; 2009 Jul;21 Suppl 1:S28-30
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic mucosal resection (EMR) and endoscopic piecemeal resection (EPMR) are therapeutic options widely accepted for the treatment of colon adenoma, intramucosal cancer and minimally invasive submucosal cancer.
  • [MeSH-major] Adenoma / surgery. Colonoscopy / methods. Colorectal Neoplasms / surgery. Intestinal Mucosa / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691729.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


26. Lim YJ, Kwack WG, Lee YS, Hahm KB, Kim YK: Increased pulse wave velocity reflecting arterial stiffness in patients with colorectal adenomas. J Clin Biochem Nutr; 2010 Nov;47(3):261-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased pulse wave velocity reflecting arterial stiffness in patients with colorectal adenomas.
  • The obese patients with diabetes or cardiovascular risk factors are associated with increased risk of colorectal cancer as well as adenomas under the shared pathogenesis related to atherosclerosis.
  • Here we determined the association between increased arterial stiffness and colorectal adenomas incorporating parameters including age, gender, waist circumference, body mass index, lipid profiles, fasting glucose, and blood pressure.
  • Subjects who simultaneously underwent colonoscopies and pulse wave velocity (PWV) determinations between July 2005 and September 2006 were analyzed, based on which the subjects were classified into two groups as patients group with colorectal adenomas (n = 49) and control group (n = 200) with normal, non-polypoid benign lesions or hyperplastic polyps.
  • Uni- and multi-variate analyses were performed to calculate the odd ratio for colon adenomas.
  • Based on uni-variate analysis, age, waist circumference, body mass index, heart-femoral PWV (hfPWV), and brachial-ankle PWV were significantly associated with adenomas (p<0.05) and multiple logistic regression analysis showed that the heart-femoral PWV, waist circumference, and the levels of LDL-C were significant risk factor for colorectal adenoma.
  • However, arterial stiffness did not affect the progression of colon adenoma.
  • The finding that hfPWV, reflecting aortic stiffness, was increased in patients with colorectal adenomas lead to conclusion that patients who have prominently increased arterial stiffness can be recommended to undergo colonoscopic examinations and at the same time we also recommend counseling about the risk for atherosclerosis in those who have colorectal adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103036.001).
  • [ISSN] 1880-5086
  • [Journal-full-title] Journal of clinical biochemistry and nutrition
  • [ISO-abbreviation] J Clin Biochem Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2966937
  • [Keywords] NOTNLM ; atherosclerosis / colon adenoma / pulse wave velocity / risk factors
  •  go-up   go-down


27. Wu K, Giovannucci E, Byrne C, Platz EA, Fuchs C, Willett WC, Sinha R: Meat mutagens and risk of distal colon adenoma in a cohort of U.S. men. Cancer Epidemiol Biomarkers Prev; 2006 Jun;15(6):1120-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meat mutagens and risk of distal colon adenoma in a cohort of U.S. men.
  • We examined the association between intakes of the heterocyclic amines 2-amino-3,8-dimethylimidazo[4,5,-f]quinoxaline (MeIQx), 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,4,8-trimethylimidazo[4,5,-f]quinoxaline (DiMeIQx), and meat-derived mutagenicity (MDM) and risk of distal colon adenoma using a cooking method questionnaire administered in 1996 in the Health Professionals Follow-up Study cohort.
  • Between 1996 and 2002, 581 distal colon adenoma cases were identified.
  • Higher intake of MDM was marginally associated with increased risk of distal adenoma [fourth versus lowest quintile: odds ratio (OR), 1.39; 95% confidence interval (95% CI), 1.05-1.84; highest versus lowest quintile: OR, 1.29; 95% CI, 0.97-1.72; P(trend) = 0.08].
  • Our data also suggested a positive association between higher MeIQx (highest versus lowest quintile: OR, 1.28; 95% CI, 0.95-1.71; P(trend) = 0.22) and risk of adenoma, but this association was attenuated after adjusting for processed meat intake.
  • DiMeIQx and PhIP did not seem to be associated with risk of adenoma.
  • In conclusion, higher consumption of mutagens from meats cooked at higher temperature and longer duration may be associated with higher risk of distal colon adenoma independent of overall meat intake.
  • Because mutagens other than heterocyclic amines also contribute to MDM, our results suggest that mutagens other than heterocyclic amines in cooked meats may also play a role in increasing the risk of distal adenoma.
  • [MeSH-major] Adenoma / etiology. Colonic Neoplasms / etiology. Meat. Mutagens / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16775169.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 55075; United States / NCI NIH HHS / CA / CA95589
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Mutagens
  •  go-up   go-down


28. Stübinger SH, van der Horst Ch, Braun PM: [Pelvic tumors in the eyes of urologists]. Ther Umsch; 2007 Jul;64(7):395-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Raumforderungen im kleinen Becken aus Sicht des Urologen.
  • Benign tumors such as endometrial myoma, ovarian cyst and adenoma of the colon might lead to the development of urogenital symptoms.
  • This is also the case with malignant tumors of the uterus, ovaries, cervix and colon where infiltration of the urogenital organs might be noted.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948757.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


29. Marino M, Galluzzo P, Leone S, Acconcia F, Ascenzi P: Nitric oxide impairs the 17beta-estradiol-induced apoptosis in human colon adenocarcinoma cells. Endocr Relat Cancer; 2006 Jun;13(2):559-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide impairs the 17beta-estradiol-induced apoptosis in human colon adenocarcinoma cells.
  • By contrast, E2 reduces the incidence of colon adenoma and carcinoma by about 30%.
  • We report the genomic and non-genomic E2-estrogen receptor (ER) beta-induced effects in human colon adenocarcinoma.
  • The E2-ERbeta-dependent gene transcription was inhibited by exogenous NO, whereas some non-genomic E2-dependent effects (e.g. p38/MAP kinase), important for the activation of the apoptotic cascade, were unaffected by NO.
  • However, NO impaired the E2-induced pro-apoptotic cascade in human colon adenocarcinoma cells by inhibiting caspase-3.
  • On the whole, high NO concentrations suppressed the E2 protective effects in the gastrointestinal tract, suggesting that the caspase-dependent apoptotic cascade may become critical under conditions of high redox stress such as occur under specific activation of the immune system by chronic infections or pathogen challenge.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / drug effects. Caspase Inhibitors. Colonic Neoplasms / metabolism. Estrogen Receptor beta / antagonists & inhibitors. Nitric Oxide / toxicity

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728582.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caspase Inhibitors; 0 / Estrogen Receptor beta; 31C4KY9ESH / Nitric Oxide; 4TI98Z838E / Estradiol; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; K848JZ4886 / Cysteine
  •  go-up   go-down


30. Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep; 2007 Mar 28;1:9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report.
  • BACKGROUND: Germ-cell testicular cancer has not been definitively linked to any known hereditary cancer susceptibility disorder.
  • His evaluation as part of an etiologic study of familial testicular cancer revealed multiple colon polyps (adenomatous, hyperplastic, and hamartomatous) first found in his 50 s, multiple lipomas, multiple hyperpigmented skin lesions, left kidney cancer diagnosed at age 64, and a growth-hormone producing pituitary adenoma with associated acromegaly diagnosed at age 64.
  • Alternatively, this family's phenotype might represent a novel neoplasm susceptibility disorder.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):629-31 [15799199.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):662-6 [15185875.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):363-71 [15172357.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):984-92 [12569597.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Hum Mol Genet. 2006 Feb 1;15(3):443-51 [16407372.001]
  • (PMID = 17411461.001).
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP11019
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1847830
  •  go-up   go-down


31. Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH, Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW, Huang CY: Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells. Mol Cell Biochem; 2006 Sep;289(1-2):101-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells.
  • Epidemiologic studies reported that the prevalence of hereditary non-polyposis colon cancer (HNPCC) in male is about 1.5-fold higher than that in female.
  • Patients that received E(2) replacement therapy were found to have a reduction in the incidence of colon adenoma and carcinoma.
  • [MeSH-major] Apoptosis. Colonic Neoplasms / pathology. Estrogen Receptor alpha / metabolism. Gene Expression Regulation. Signal Transduction. Tumor Necrosis Factor-alpha / genetics. beta Catenin / metabolism
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / metabolism. Caspases / metabolism. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Cell Proliferation. DNA Fragmentation. Down-Regulation / genetics. Estrogens / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic / drug effects. Transfection. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism. Up-Regulation / genetics. Wnt Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628468.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cell Cycle Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53; 0 / Wnt Proteins; 0 / beta Catenin; EC 3.4.22.- / Caspases
  •  go-up   go-down


32. Hsu HH, Cheng SF, Wu CC, Chu CH, Weng YJ, Lin CS, Lee SD, Wu HC, Huang CY, Kuo WW: Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol; 2006 Apr 30;49(2):110-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner.
  • Epidemiologic studies reported that the prevalence of hereditary non-polyposis colon cancer (HNPCC) in male is about 1.5-fold higher than that in female.
  • Patients that received E2 replacement therapy were found to have a reduction in the incidence of colon adenoma and carcinoma.
  • [MeSH-major] Apoptosis. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Estrogen Receptor beta / metabolism. Signal Transduction. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Chin J Physiol. 2006 Jun 30;49(3):167
  • (PMID = 16830793.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Estrogen Receptor beta; 0 / Ligands; 0 / Recombinant Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


33. Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, Juliana MM, Grubbs CJ, Lubet RA: Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res (Phila); 2009 Nov;2(11):951-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.
  • Nonsteroidal anti-inflammatory drugs (NSAID) have been highly effective in preventing colon, urinary bladder, and skin cancer preclinically, and also in clinical trials of colon adenoma formation.
  • In the azoxymethane-induced rat colon aberrant crypt foci (ACF) model, naproxen administered at 200 and 400 ppm in the diet reduced mean ACFs in the colon by about 45% to 60%, respectively.
  • These data show that both naproxen and NO-naproxen are effective agents against urinary bladder and colon, but not mammary, carcinogenesis.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NAPROXEN .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6187-92 [3167865.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):324-30 [15242680.001]
  • [Cites] J Cell Biochem Suppl. 1992;16G:55-62 [1361589.001]
  • [Cites] Biometrics. 1993 Mar;49(1):259-68 [8513108.001]
  • [Cites] Carcinogenesis. 1993 Aug;14(8):1493-7 [8353834.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4182-8 [8364913.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1464-72 [7882354.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):355-60 [9162301.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Ann Rheum Dis. 2005 Mar;64(3):449-56 [15345500.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Scand J Gastroenterol. 2006 Mar;41(3):264-73 [16497612.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1232-9 [16344269.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1214-21 [16352617.001]
  • [Cites] BMJ. 2006 Jun 3;332(7553):1302-8 [16740558.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1530-8 [16818512.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] JAMA. 2006 Oct 4;296(13):1619-32 [16968832.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):2022-8 [17620432.001]
  • [Cites] Am J Clin Dermatol. 2007;8(4):195-200 [17645375.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96 [17875779.001]
  • [Cites] Acta Pharmacol Sin. 2008 Jan;29(1):1-20 [18158862.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2908-18 [18853980.001]
  • [Cites] Clin Pharmacol Ther. 2009 Feb;85(2):190-7 [18987620.001]
  • [Cites] Trends Pharmacol Sci. 2009 Mar;30(3):112-7 [19230986.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):293-7 [10667579.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5599-602 [11059745.001]
  • [Cites] Mutat Res. 2003 Feb-Mar;523-524:137-44 [12628511.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):29-42 [14965265.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):36-44 [15179622.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5270-4 [1913650.001]
  • (PMID = 19892664.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01 CN043301; United States / NCI NIH HHS / CN / NCI-CN43301; United States / NCI NIH HHS / CA / N01CN53300; United States / NCI NIH HHS / CN / NCI-CN53300; United States / NCI NIH HHS / CN / N01 CN053300; United States / NCI NIH HHS / CA / N01CN43301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Carcinogens; 0 / Nitric Oxide Donors; 0 / naproxen-n-butyl nitrate; 3817-11-6 / Butylhydroxybutylnitrosamine; 57Y76R9ATQ / Naproxen; 684-93-5 / Methylnitrosourea; MO0N1J0SEN / Azoxymethane
  • [Other-IDs] NLM/ NIHMS142040; NLM/ PMC2774912
  •  go-up   go-down


34. Muthunayagam NP, Rohrer JE, Wright SE: Correlation of iron and colon adenomas. Gastroenterol Clin Biol; 2009 May;33(5):435-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of iron and colon adenomas.
  • BACKGROUND AND OBJECTIVE: Better colon cancer screening guidelines are needed.
  • This study was conducted to explore the relationship between serum transferrin saturation (as iron is a potential carcinogen) and presence of colon adenomas.
  • This may aid to evolve better colon cancer screening guidelines.
  • The adjusted odds ratio, derived from multiple logistic regression analysis, was used to measure the association between transferrin saturation and colon adenomas.
  • The adjusted odds ratio, for predicting the presence of polyp in those patients with transferrin saturation above the median was 10.9 (CI 4.0-29.5, P<0.001).
  • A one percent increase in transferrin saturation was associated with a 1.07 increase the odds of adenoma (CI 1.03-1.11, P<0.001).
  • CONCLUSIONS: Iron levels are directly linked to presence of colon polyps, and might help in evolving better screening guidelines.
  • [MeSH-major] Adenoma / blood. Adenoma / etiology. Colonic Neoplasms / blood. Colonic Neoplasms / etiology. Iron Overload / complications. Transferrin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144479.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Transferrin
  •  go-up   go-down


35. Kaczka A, Kumor A, Pietruczuk M, Małecka-Panas E: [Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer]. Pol Merkur Lekarski; 2007 May;22(131):373-5
MedlinePlus Health Information. consumer health - Diabetes Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer].
  • Colon carcinogenesis is a multi-steps process in which many growth factors are involved.
  • In some studies the increased risk of colon cancer development was observed in patients with diabetes mellitus type 2 with accompanying hyperinsulinemia.
  • The aim of the study was to evaluate the serum concentration of insulin, C-peptide and IGF-I in patients with colon adenomas and colorectal cancer.
  • MATERIALS AND METHODS: In 17 patients with colon cancer, 32 patients with colon adenomas and in 12 healthy persons the serum concentration of insulin, C-peptide and IGF-I was determined using ELISA kits.
  • RESULTS: In patients with colon cancer significantly higher serum IGF-I concentration comparing to the control group was observed (85.66 ng/ml vs. 60.96 ng/ml; p < 0.05).
  • In patients with colon adenomatous polyps we also observed higher serum IGF-I concentrations I comparing to the control group (82.1 ng/ml vs. 60.96 ng/ml), in high dysplasia adenomas (84.12 ng/ml vs. 79.67 ng/ml) and in smaller adenomas to 1 cm diameter (97.98 ng/ml vs. 73.28 ng/ml), but the differences were not significant.
  • We also observed higher concentration of C-peptide in patients with low grade dysplasia adenomas (665.24 pmol/l vs. 498.13 pmol/l) and with small polyps (611.51 pmol/l vs. 514.89 pmol/l).
  • There were no differences in serum concentration of IGF-I and C-peptide between patients with tubular and villous adenomas.
  • CONCLUSIONS: IGF-I is probably involved particularly in the early stage of colon carcinogenesis.
  • [MeSH-major] Adenoma / blood. Adenomatous Polyps / blood. C-Peptide / blood. Colonic Polyps / blood. Colorectal Neoplasms / blood. Insulin / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679371.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / C-Peptide; 0 / Insulin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


36. Becker JC, Fukui H, Imai Y, Sekikawa A, Kimura T, Yamagishi H, Yoshitake N, Pohle T, Domschke W, Fujimori T: Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand J Gastroenterol; 2007 Jul;42(7):852-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer.
  • OBJECTIVE: Heme oxygenase-1 (HO-1) has emerged as a crucial mediator of mucosal defense in the gastrointestinal tract.
  • The role of HO-1 in gastrointestinal malignancies, however, remains to be elucidated.
  • The purpose of this study was to analyze HO-1 expression in human colon adenoma and cancer samples.
  • MATERIAL AND METHODS: Fifty-five paraffin-embedded surgical specimens of colorectal cancer and 19 colonic adenoma samples were stained immunhistochemically for HO-1 expression using an anti-HO-1 monoclonal antibody.
  • HO-1 expression was evaluated independently by two different investigators and subsequently correlated to clinical data and patients' life expectancy.
  • RESULTS: Focal HO-1 expression could be documented in 41.8% (23/55) of patients with colorectal cancer.
  • HO-1 expression in colonic adenoma was detectable in 36.8% (7/19) of cases.
  • The rate of lymphatic tumor invasion was significantly lower in colorectal cancer samples expressing HO-1 (p=0.048).
  • Additionally, fewer lymph node metastases were found in colorectal cancer samples with HO-1 expression, but these differences did not reach statistical significance.
  • Kaplan-Meier analysis showed a significantly better survival for colorectal cancer patients with colonic HO-1 expression (p=0.018).
  • CONCLUSIONS: This study demonstrates that colonic HO-1 may be a prognostic marker of colorectal-cancer outcome.
  • [MeSH-major] Adenoma / enzymology. Biomarkers, Tumor / metabolism. Colon / enzymology. Colorectal Neoplasms / enzymology. Heme Oxygenase-1 / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558910.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.3 / Heme Oxygenase-1
  •  go-up   go-down


37. Liu ES, Ye YN, Shin VY, Wu WK, Wong BC, Cho CH: Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice. Cancer Invest; 2007 Dec;25(8):750-7
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The interactions of cigarette smoking with COX-2 on colitis and colitis-associated adenoma formation were studied.
  • Results indicated that CS did not alter acute colonic inflammation.
  • Chronic SC236 treatment abolished the promoting effect of CS on colonic adenoma formation, via suppression of COX-2- and VEGF-mediated proliferation and angiogenesis, and reversed bcl-2-mediated inhibition of apoptosis by CS.
  • [MeSH-major] Adenoma / etiology. Colitis, Ulcerative / complications. Colonic Neoplasms / etiology. Cyclooxygenase 2 / physiology. Pyrazoles / therapeutic use. Smoking / adverse effects. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058473.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 0 / Pyrazoles; 0 / Sulfonamides; 9042-14-2 / Dextran Sulfate; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


38. Kitayama J, Tabuchi M, Tsurita G, Ishikawa M, Otani K, Nagawa H: Adiposity and gastrointestinal malignancy. Digestion; 2009;79 Suppl 1:26-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our retrospective studies show that hypertriglyceridemia is an independent risk factor for the development of colonic adenoma and nodal metastasis in early gastric and esophageal cancer in men.
  • [MeSH-major] Adenoma / etiology. Adiposity. Carcinoma / etiology. Colorectal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153487.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adiponectin
  •  go-up   go-down


39. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW, Jones DA: A two-step model for colon adenoma initiation and progression caused by APC loss. Cell; 2009 May 15;137(4):623-34
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-step model for colon adenoma initiation and progression caused by APC loss.
  • Aberrant Wnt/beta-catenin signaling following loss of the tumor suppressor adenomatous polyposis coli (APC) is thought to initiate colon adenoma formation.
  • These findings suggest that, following APC loss, CtBP1 contributes to adenoma initiation as a first step, whereas KRAS activation and beta-catenin nuclear localization promote adenoma progression to carcinomas as a second step.
  • Consistent with this model, human FAP adenomas showed robust upregulation of CtBP1 in the absence of detectable nuclear beta-catenin, whereas nuclear beta-catenin was detected in carcinomas.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4456-62 [15483017.001]
  • [Cites] EMBO J. 2000 May 15;19(10):2270-9 [10811618.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51581-9 [15358764.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9369-80 [15516977.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26565-72 [15899904.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30490-5 [15967793.001]
  • [Cites] Gene. 2005 Nov 21;361:1-12 [16185824.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):586-600 [16510874.001]
  • [Cites] EMBO Rep. 2006 Apr;7(4):444-9 [16439994.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):9971-6 [16476742.001]
  • [Cites] EMBO J. 2006 Jun 21;25(12):2735-45 [16710294.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13409-14 [16938888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37828-35 [17028196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4036-41 [17360473.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2469-79 [17363564.001]
  • [Cites] Am J Med Genet A. 2007 Jul 1;143A(13):1472-80 [17551924.001]
  • [Cites] J Biol Chem. 2007 Oct 5;282(40):29394-400 [17673467.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9721-30 [17942902.001]
  • [Cites] Science. 2008 Jan 18;319(5861):333-6 [18202290.001]
  • [Cites] Cell. 2008 Apr 18;133(2):340-53 [18423204.001]
  • [Cites] Nat Genet. 2008 May;40(5):600-8 [18372904.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • [Cites] Cell. 2000 Oct 13;103(2):311-20 [11057903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8683-8 [12072559.001]
  • [Cites] Curr Biol. 2002 Jul 23;12(14):R499-R501 [12176352.001]
  • [Cites] Am J Clin Pathol. 2003 Sep;120(3):418-23 [14502807.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):633-7 [14534590.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1385-90 [15198980.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):528-35 [15363803.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43261-72 [15294912.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):298-303 [2438556.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4624-30 [9377578.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1021-6 [9500465.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):15-21 [10072352.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1442-4 [10197610.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3875-9 [10463573.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):677-85 [15525529.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7219-25 [10602475.001]
  • (PMID = 19450512.001).
  • [ISSN] 1097-4172
  • [Journal-full-title] Cell
  • [ISO-abbreviation] Cell
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA073992; United States / NCI NIH HHS / CA / CA116468-03; United States / NCI NIH HHS / CA / CA073992-06A10003; United States / NCI NIH HHS / CA / R01 CA116468-03; United States / NCI NIH HHS / CA / CA96934; United States / NCI NIH HHS / CA / P01 CA073992-06A10003; United States / NCI NIH HHS / CA / R01 CA116468; United States / NCI NIH HHS / CA / P01 CA073992; United States / NCI NIH HHS / CA / CA116468-04; United States / NCI NIH HHS / CA / CA042014; United States / NCI NIH HHS / CA / P30 CA042014; United States / NCI NIH HHS / CA / R01 CA116468-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / DNA-Binding Proteins; 0 / Peptide Fragments; 0 / Rac1 GTP-binding protein (17-32); 0 / beta Catenin; EC 1.1.- / Alcohol Oxidoreductases; EC 1.1.1.- / C-terminal binding protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.6.5.2 / rac1 GTP-Binding Protein; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS102940; NLM/ PMC2706149
  •  go-up   go-down


40. Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL, Wang YH: Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol; 2005 Jun 21;11(23):3632-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.
  • AIM: To detect the expression of Fas ligand (FasL) in colon cancer tissues and cell lines and analyze the function of FasL-expressing colon cancer cells in inducing Fas-sensitive T lymphocyte apoptosis.
  • METHODS: Ninety surgically resected colon cancer tissues and 15 hepatic metastasis specimens were investigated by immunohistochemical method with normal colon mucosa and colon adenoma as control.
  • FasL expression of 4 colon cancer cell lines, SW620, Lovo, LS-174T and SW1116, were detected by Western blotting assay.
  • The function of FasL expressed on colon cancer cells was determined by coculture assay with Jurkat T lymphocytes, the apoptotic rate of which was detected by flow cytometry assay.
  • RESULTS: Fifty-six (62.22%) cases of all the 90 colon cancer tissues and all (100%) the liver metastasis specimens expressed FasL, significantly higher than normal colon mucosa and colonic adenoma.
  • Higher expression of FasL was found in more advanced stage of colon cancer and in cancer tissues with lymphatic or hepatic metastasis.
  • All the colon cancer cell lines were found to express FasL.
  • CONCLUSION: The expression of FasL is upregulated in colon cancer and the functionally expressed FasL can induce apoptosis of Fas-expressing T lymphocytes.
  • [MeSH-major] Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962391.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ PMC4315977
  •  go-up   go-down


41. Yuan B, Jin X, Zhu R, Zhang X, Liu J, Wan H, Lu H, Shen Y, Wang F: Cronkhite-Canada syndrome associated with rib fractures: a case report. BMC Gastroenterol; 2010;10:121
MedlinePlus Health Information. consumer health - Osteoporosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophagogastroduodenoscopy, video capsule endoscopy and colonoscopy revealed various sizes of generalized gastrointestinal polyps.
  • Histological examination of the biopsy specimens obtained from the stomach and the colon showed adenomatous polyp and inflammatory polyp respectively.

  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):388-91 [11522989.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Mar;16(3):333-42 [11876685.001]
  • [Cites] Expert Opin Pharmacother. 2003 Mar;4(3):385-9 [12614190.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1444-6 [12818298.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):570-2 [18294523.001]
  • [Cites] Medicine (Baltimore). 1982 Sep;61(5):293-309 [7109958.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):537-41 [9434222.001]
  • [Cites] N Engl J Med. 1955 Jun 16;252(24):1011-5 [14383952.001]
  • [Cites] Digestion. 2007;75(2-3):96-7 [17510553.001]
  • [Cites] Digestion. 2004;69(1):57-62 [14755154.001]
  • (PMID = 20955587.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2972238
  •  go-up   go-down


42. Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis; 2010 Sep;25(5):463-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients.
  • Oxidative stress is involved in the pathogenesis of colon cancer.
  • In the examined groups of patients with colorectal cancer (CRC, n = 89), benign adenoma (AD, n = 77) and healthy volunteers (controls, n = 99), we measured: vitamins A, C and E in blood plasma, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanine (8-oxoGua) in leukocytes and urine, leukocyte 8-oxoGua excision activity, mRNA levels of APE1, OGG1, 8-oxo-7,8-dihydrodeoxyguanosine 5'-triphosphate pyrophosphohydrolase (MTH1) and OGG1 polymorphism.
  • The vitamin levels decreased gradually in AD and CRC patients.
  • 8-OxodG increased in leukocytes and urine of CRC and AD patients.
  • 8-OxoGua excision was higher in CRC patients than in controls, in spite of higher frequency of the OGG1 Cys326Cys genotype, encoding a glycosylase with decreased activity. mRNA levels of OGG1 and APE1 increased in CRC and AD patients, which could explain increased 8-oxoGua excision rate in CRC patients.
  • The results suggest that oxidative stress occurs in CRC and AD individuals.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Repair / genetics. Deoxyguanosine / analogs & derivatives. Oxidative Stress / genetics
  • [MeSH-minor] Adenomatous Polyps / blood. Adenomatous Polyps / metabolism. Adult. Aged. Aging / genetics. Antioxidants / metabolism. Case-Control Studies. DNA Glycosylases / genetics. DNA Glycosylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Polymorphism, Single Nucleotide / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sex Characteristics. Smoking / adverse effects. Smoking / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534734.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.6.- / 8-oxodGTPase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; EC 6.5.1.- / DNA Repair Enzymes; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


43. Deutscher N, Bataille F, Hausmann M, Kiessling S, Muller-Newen G, Leeb SN, Herfarth H, Heinrich PC, Schölmerich J, Rogler G: Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. Int J Colorectal Dis; 2006 Sep;21(6):573-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer.
  • The aim of this study was to investigate the expression profiling of IL-11Ralpha and its downstream signaling cascade in colonic adenoma and carcinoma.
  • MATERIALS AND METHODS: The expression of IL-11Ralpha in normal colonic mucosa, 11 colonic adenomas, and 10 carcinomas was analyzed by immunohistochemistry.
  • RESULTS: Immunohistochemistry revealed significant IL-11-Ralpha expression in epithelial cells of normal colonic mucosa.
  • In contrast, the expression of IL-11-Ralpha in colon adenomas and carcinomas was either absent or only detectable in very few scattered epithelial cells.
  • Densitometric analysis of Western blots confirmed these results, showing a decrease of IL-11Ralpha-protein in cells isolated from adenomas or carcinomas.
  • CONCLUSION: This study demonstrates a decrease of IL-11-Ralpha-protein expression in epithelial cells isolated from colon carcinomas and adenomas compared to normal colonic mucosa and a reduced STAT3 signaling.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Colonic Neoplasms / metabolism. Interleukin-11 Receptor alpha Subunit / biosynthesis. Intestinal Mucosa / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292518.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-11 Receptor alpha Subunit
  •  go-up   go-down


44. du Toit J, Hamilton W, Barraclough K: Risk in primary care of colorectal cancer from new onset rectal bleeding: 10 year prospective study. BMJ; 2006 Jul 8;333(7558):69-70
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To measure the risk of colorectal cancer and adenoma with new onset rectal bleeding reported to primary care.
  • MAIN OUTCOME MEASURES: Percentage of participants in whom colorectal cancer or colonic adenoma was identified after investigation of the bowel.
  • Of these, 15 (5.7%, 95% confidence interval 3.2% to 9.2%) had colorectal cancer, and 13 (4.9%, 2.6% to 8.4%) had colonic adenoma.
  • CONCLUSIONS: One in 10 patients aged 45 or more with new onset rectal bleeding had colonic neoplasia, so investigation of the bowel should be offered to all such patients, whether or not they have other symptoms.
  • [MeSH-major] Adenoma / etiology. Colorectal Neoplasms / etiology. Gastrointestinal Hemorrhage / etiology. Rectal Diseases / etiology


45. Zhou JN, Chen SQ, Zhang XM, Zhou X, Zhu M, Feng B, Li JT, Ma GJ, Zhang YY: [A novel APC gene germline mutation in a familial adenomatous polyposis pedigree]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug;23(4):388-91
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A novel APC gene germline mutation in a familial adenomatous polyposis pedigree].
  • OBJECTIVE: To detect the adenomatous polyposis coli (APC) gene germline mutation in the proband and her family members with familial adenomatous polyposis (FAP).
  • This mutation manifested an aggressive form of FAP with early onset of colorectal adenocarcinoma and colonic adenoma.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli Protein / genetics. Germ-Line Mutation

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883523.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  •  go-up   go-down


46. Lau PC, Sung JJ: Flat adenoma in colon: two decades of debate. J Dig Dis; 2010 Aug;11(4):201-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flat adenoma in colon: two decades of debate.
  • The existence of flat adenomas in the colon is well recognized.
  • Whether they represent a distinct disease with a pathogenetic pathway different from that of the classical adenoma-carcinoma sequence in colorectal tumorigenesis and have higher malignant potential remains a matter of debate.
  • To review the epidemiology, clinical features, detection and management of flat and depressed (non-polypoid) colonic neoplasm, we performed a thorough literature review on studies focusing on the prevalence, histological features, genetics, detection and treatment of flat and depressed (non-polypoid) colonic neoplasm.
  • A high percentage of severe dysplasia in flat colonic adenomas has not been consistently demonstrated.
  • Flat adenomas are found to have a lower incidence of major genetic abnormalities involved in the classical adenoma-carcinoma sequence and that has raised suspicions that they may have a different pathogenesis.
  • More advanced colonoscopic techniques, such as chromoendoscopy, may enhance the detection of small and inconspicuous colonic neoplastic lesions that lack a protruding configuration.
  • It is essential for endoscopists to appreciate the existence and clinical significance of flat and depressed colonic lesions as an important variant of colonic neoplasms so that the goal of reducing colorectal carcinoma incidence by polypectomy can be better achieved.
  • [MeSH-major] Adenoma. Colonic Neoplasms
  • [MeSH-minor] Colonic Polyps / epidemiology. Colonic Polyps / genetics. Colonic Polyps / pathology. Colonic Polyps / therapy. Colonoscopy. Humans. Rectal Neoplasms / epidemiology. Rectal Neoplasms / genetics. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20649732.001).
  • [ISSN] 1751-2980
  • [Journal-full-title] Journal of digestive diseases
  • [ISO-abbreviation] J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  •  go-up   go-down


47. Lü BJ, Cui J, Xu J, Zhang H, Luo MJ, Zhu YM, Lai MD: [Bioinformatic analysis of adenoma-normal mucosa SSH library of colon]. Yi Chuan; 2006 Apr;28(4):385-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bioinformatic analysis of adenoma-normal mucosa SSH library of colon].
  • We established a colonic adenoma-normal mucosa suppressive subtraction hybridization (SSH) library in 1999.
  • The nucleic acid analytical software, an integrator of the universal bioinformatics tools including phred, phd2fasta, cross_match, repeatmasker and blast2.0, can blast sequences of differential clones with the downloaded non-redundant nucleotide (NR) database.
  • Both genes were up-regulated in 10 or 9 out of 10 adenomas in comparison with the paired normal mucosa, respectively.
  • The candidate genes in A-N library would be of great significance in disclosing the molecular mechanism underlying in colonic adenoma initiation and progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606587.001).
  • [ISSN] 0253-9772
  • [Journal-full-title] Yi chuan = Hereditas
  • [ISO-abbreviation] Yi Chuan
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Mego M, Májek J, Konceková R, Ebringer L, Cierniková S, Rauko P, Kovác M, Trupl J, Slezák P, Zajac V: Intramucosal bacteria in colon cancer and their elimination by probiotic strain Enterococcus faecium M-74 with organic selenium. Folia Microbiol (Praha); 2005;50(5):443-7
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramucosal bacteria in colon cancer and their elimination by probiotic strain Enterococcus faecium M-74 with organic selenium.
  • Intraepithelial bacteria were isolated by the gentamicin protection assay (GPA) from biopsy samples obtained at colonoscopy (colon cancer, n = 10 patients; colonic adenoma, n = 20; control group, n = 20; cancer patients without gastrointestinal tract GIT malignancy, n = 10).
  • The number of biopsies with intracellular bacteria was significantly higher in adenoma and carcinoma group than in control group (26 vs. 10%; p = 0.004); in cancer patients without GIT malignancy the difference was nonsignificant. E. faecium M-74 was also administered to 5 patients with colonic adenoma; according to a control colonoscopy the number of biopsies with intracellular bacteria was significantly lower after probiotic administration (48 vs. 16%; p = 0.03).
  • A striking prevalence of intraepithelial bacteria was also showed in patients with large bowel adenoma and carcinoma.
  • The administration of probiotic strain M-74 can thus be considered to be an effective and promising method for elimination of pathogenic bacteria in the case of inflammatory bowel disease and colon cancer.
  • [MeSH-major] Colonic Neoplasms / microbiology. Enterobacteriaceae / isolation & purification. Enterococcus faecium. Intestinal Mucosa / microbiology. Probiotics / administration & dosage
  • [MeSH-minor] Adenoma / microbiology. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Selenium / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475505.001).
  • [ISSN] 0015-5632
  • [Journal-full-title] Folia microbiologica
  • [ISO-abbreviation] Folia Microbiol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] H6241UJ22B / Selenium
  •  go-up   go-down


49. Agostini M, Tibiletti MG, Lucci-Cordisco E, Chiaravalli A, Morreau H, Furlan D, Boccuto L, Pucciarelli S, Capella C, Boiocchi M, Viel A: Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol; 2005 Aug;100(8):1886-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor family history of a patient with cafè-au-lait spots (CALS) and early onset adenomas, duodenal cancer, and glioblastoma was positive for colonic adenoma (mother), jejunal (maternal grandfather), lung (father), and colorectal (paternal uncle) cancers.
  • Our findings point out the association between PMS2 and TS, and support the hypothesis that patients with a few polyps, small bowel tumors with a very early onset, glioblastoma, and CALS should be considered as a variant of hereditary nonpolyposis colorectal cancer.

  • Genetic Alliance. consumer health - Turcot syndrome.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16144131.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


50. Pap Z, Pávai Z, Dénes L, Kovalszky I, Jung J: An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1. Pathol Oncol Res; 2009 Dec;15(4):579-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1.
  • Our goal was to study the changes in the expression of these molecules during colon carcinoma development and progression.
  • We tested 117 colon adenomas and 149 de novo and ex adenoma carcinomas of the colon, using the Ultravision Polymer system.
  • The positive reaction rate was 100% for E-cadherin, 98.3% for syndecan-1 and 22.4% for Ets-1 in adenomas, while in carcinomas it was 88.5%, 62.4% and 56.3% respectively.
  • We found decreasing expression of E-cadherin and syndecan-1 throughout colon carcinoma progression and an opposite regulation for the Ets-1 protein.
  • De novo carcinomas have lower E-cadherin and syndecan-1 expression, and higher Ets-1 expression compared to ex adenoma carcinomas.
  • [MeSH-major] Adenoma / metabolism. Cadherins / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. Proto-Oncogene Protein c-ets-1 / metabolism. Syndecan-1 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253033.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Proto-Oncogene Protein c-ets-1; 0 / Syndecan-1
  •  go-up   go-down


51. Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, Takkikto M, Hewitt S, Lee EL, Dashwood RH, Smoot D: Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci; 2009 Oct;54(10):2109-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma.
  • Chromatin remodeling and activation of transcription are important aspects of gene regulation, but these often go awry in disease progression, including during colon cancer development.
  • We investigated the status of global histone acetylation (by measuring H3, H4 acetylation of lysine residues, which also occur over large regions of chromatin including coding regions and non-promoter sequences) and expression of histone deacetylase 2 (HDAC2) in colorectal cancer (CRC) tissue microarrays using immunohistochemical staining.
  • Specifically, HDAC2 and the acetylation of histones H4K12 and H3K18 were evaluated in 134 colonic adenomas, 55 moderate to well differentiated carcinomas, and 4 poorly differentiated carcinomas compared to matched normal tissue.
  • HDAC2 nuclear expression was detected at high levels in 81.9%, 62.1%, and 53.1% of CRC, adenomas, and normal tissue, respectively (P = 0.002).
  • HDAC2 expression was correlated significantly with progression of adenoma to carcinoma (P = 0.002), with a discriminative power of 0.74, when comparing cancer and non-cancer cases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5540-53 [10891493.001]
  • [Cites] Lung Cancer. 2008 Jan;59(1):24-31 [17854949.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):477-83 [11673688.001]
  • [Cites] J Cell Sci. 2002 Feb 15;115(Pt 4):689-98 [11865025.001]
  • [Cites] Nature. 2002 May 23;417(6887):455-8 [12024216.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1817-23 [12087472.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):377-82 [12385581.001]
  • [Cites] Chem Biol. 2002 Nov;9(11):1167-73 [12445767.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7213-8 [12499261.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1112-7 [12631615.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:220-31 [12724227.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7398-403 [15123805.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5106-18 [15169878.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):1-16 [10825229.001]
  • [Cites] J Assoc Acad Minor Phys. 1999;10(3):59-67 [10826011.001]
  • [Cites] Cancer. 1980 Mar 15;45(5 Suppl):1185-92 [7357511.001]
  • [Cites] Cell. 1997 Aug 22;90(4):595-606 [9288740.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1670-6 [10223559.001]
  • [Cites] J Pathol. 2005 Jan;205(1):65-73 [15586362.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2684-9 [15805266.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1262-6 [15988529.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):914-9 [15856472.001]
  • [Cites] Ann Thorac Surg. 2006 Aug;82(2):396-401; discussion 401 [16863736.001]
  • [Cites] Methods Enzymol. 2006;410:400-15 [16938563.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2685-92 [17363589.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):363-9 [17555985.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):763-9 [17674041.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4358-64 [17906200.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • (PMID = 19057998.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122959; United States / NCI NIH HHS / CA / CA122959-02; United States / NCI NIH HHS / CA / R01 CA122959-02; United States / PHS HHS / / A102681; United States / NCI NIH HHS / CA / R01 CA122959
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ NIHMS118762; NLM/ PMC2737733
  •  go-up   go-down


52. Park YS: [COX-2 inhibitors in inflammatory bowel disease: friends or foes?]. Korean J Gastroenterol; 2007 Dec;50(6):350-5
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • COX-2 is frequently overexpressed in colonic adenoma and carcinoma.
  • Specific inhibitors of COX-2 have been shown to induce apoptosis in tumor cells and to inhibit tumor growth in animal models and in humans.
  • In a recent study, powerful chemopreventive ability of selective COX-2 inhibitor was observed in colitis-related colon carcinogenesis in mouse model.
  • But it was reported that even selective COX inhibitors aggravated the DSS-induced colonic inflammation.
  • It is assumed that endogenous PGs are involved in the mucosal defense against DSS-induced colonic ulcerations which are produced by COX-1 at early phase and by COX-2 at late phase.
  • Long-term use of COX-2 inhibitors for the chemoprevention of colitic cancer is needed to define their mechanism of action, that reduce side effects and have specific tumor target.
  • [MeSH-minor] Animals. Colonic Neoplasms / diagnosis. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Humans. Mice. Models, Animal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159171.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 59
  •  go-up   go-down


53. Al-Daraji WI, Abdellaoui A, Salman WD: Osseous metaplasia in a tubular adenoma of the colon. J Clin Pathol; 2005 Feb;58(2):220-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osseous metaplasia in a tubular adenoma of the colon.
  • Flexible sigmoidoscopy revealed a 1.5 cm polyp 30 cm from the anus.
  • The polyp was removed during the sigmoidoscopy by electrocautery and sent for histological examination.
  • The polyp was a tubular adenoma with mild dysplasia.
  • The adenoma contained numerous foci of metaplastic bone.
  • This is the first case of osseous metaplasia in a tubular adenoma of the colon to be reported.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Ossification, Heterotopic / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Colon / pathology. Female. Humans. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1981 Aug;27(3):198-9 [7297837.001]
  • [Cites] Scand J Gastroenterol. 2000 May;35(5):556-8 [10868462.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1968 Nov;104(3):561-5 [5687904.001]
  • [Cites] J Can Assoc Radiol. 1962 Dec;13:135-9 [13960743.001]
  • [Cites] Hum Pathol. 1989 Jan;20(1):86-8 [2492256.001]
  • [Cites] Arch Pathol Lab Med. 1994 Jan;118(1):64-5 [8285834.001]
  • [Cites] Am J Pathol. 1955 Jan-Feb;31(1):73-91 [13218132.001]
  • [Cites] Ann Pathol. 1988;8(1):64-6 [3134902.001]
  • (PMID = 15677548.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770563
  •  go-up   go-down


54. Georgopoulos SD, Polymeros D, Triantafyllou K, Spiliadi C, Mentis A, Karamanolis DG, Ladas SD: Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion; 2006;74(1):42-6
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypergastrinemia is associated with increased risk of distal colon adenomas.
  • BACKGROUND/AIMS: Helicobacter pylori infection is a recognized cause of hypergastrinemia, but the association of blood gastrin levels with colonic adenomas (CAs) is controversial.
  • Multivariate analysis was performed to identify risk factors for colon adenomas.
  • RESULTS: Though prevalence of H. pylori antibodies was not significantly different, the prevalence of cagA protein was significantly higher in patients with adenomas (42.3%) as compared with controls (25.6%, p < 0.03).
  • Hypergastrinemia (>110 pg/ml) was commoner in patients with CAs than in controls (29.5 vs. 11.5%, p = 0.006) and was the only independent risk factor for adenomas (odds ratio 3.2, 95% CI 1.4-7.5) by multivariate analysis, but not H. pylori infection or cagA positivity.
  • There was a significant association of hypergastrinemia and distal distribution of adenomas (p < 0.002).
  • CONCLUSIONS: Our study shows that hypergastrinemia is a risk factor for CAs, especially of the distal colon.
  • [MeSH-major] Adenoma / etiology. Antigens, Bacterial / blood. Bacterial Proteins / blood. Colonic Neoplasms / etiology. Gastrins / blood. Helicobacter Infections / complications. Helicobacter pylori

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Digestion. 2006;74(1):40-1 [17068396.001]
  • (PMID = 17068397.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Gastrins; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


55. Veeriah S, Miene C, Habermann N, Hofmann T, Klenow S, Sauer J, Böhmer F, Wölfl S, Pool-Zobel BL: Apple polyphenols modulate expression of selected genes related to toxicological defence and stress response in human colon adenoma cells. Int J Cancer; 2008 Jun 15;122(12):2647-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apple polyphenols modulate expression of selected genes related to toxicological defence and stress response in human colon adenoma cells.
  • The purpose of this study was to investigate whether polyphenols from apples modulate expression of genes related to colon cancer prevention in preneoplastic cells derived from colon adenoma (LT97).
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Flavonoids / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Malus / chemistry. Phenols / pharmacology. Precancerous Conditions / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18351577.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


56. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F, Rahman N: Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol; 2007 Feb;4(2):130-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations.
  • Background A 13-year-old girl presented with rectal bleeding and was found to have two colonic carcinomas (stage Dukes' C) and multiple colonic polyps.
  • A three-generation family history identified no relatives with colonic carcinomas or polyposis.
  • Investigations Immunohistochemical analysis was performed on a sample of colonic adenoma.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Colonic Neoplasms / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Medulloblastoma / genetics


57. Ye YN, Wu WK, Shin VY, Cho CH: A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Eur J Pharmacol; 2005 Sep 5;519(1-2):52-7
Hazardous Substances Data Bank. NICOTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mechanistic study of colon cancer growth promoted by cigarette smoke extract.
  • Our previous study showed that cigarette smoke promotes the formation of inflammation-associated colonic adenoma in mice through an angiogenic pathway.
  • Therefore, in the present study, we used the human colon adenocarcinoma cell line, SW1116, and human umbilical vascular endothelial cells (HUVECs) to elucidate the possible mechanisms in vitro.
  • Taken together, the results of the present study demonstrate the central role of 5-LOX and its relationship with angiogenic mediators in the actions of cigarette smoke in the promotion of angiogenesis during colon cancer growth.
  • [MeSH-minor] Antibodies / pharmacology. Arachidonate 5-Lipoxygenase / metabolism. Benzoquinones / pharmacology. Cell Line. Cell Line, Tumor. Coculture Techniques / methods. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. DNA / biosynthesis. Dose-Response Relationship, Drug. Endothelial Cells / drug effects. Endothelial Cells / metabolism. Humans. Lipoxygenase Inhibitors / pharmacology. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Matrix Metalloproteinase Inhibitors. Nicotine / pharmacology. Piperazines / pharmacology. Pyrimidines / pharmacology. Thymidine / metabolism. Time Factors. Tritium. Vascular Endothelial Growth Factor A / immunology. Vascular Endothelial Growth Factor A / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125168.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Benzoquinones; 0 / Lipoxygenase Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 0 / Ro 28-2653; 0 / Smoke; 0 / Vascular Endothelial Growth Factor A; 10028-17-8 / Tritium; 6M3C89ZY6R / Nicotine; 80809-81-0 / 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone; 9007-49-2 / DNA; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; VC2W18DGKR / Thymidine
  •  go-up   go-down


58. Tabuchi M, Kitayama J, Nagawa H: Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol; 2006 Feb 28;12(8):1261-4
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men.
  • AIM: To determine the real association between serum lipid levels and colonic polyp formation.
  • METHODS: We performed a large scale retrospective study to analyze the correlation between the incidence of colorectal adenoma or carcinoma and the fasting serum levels of total cholesterol (TC) and triglycerides (TG) in patients who underwent total colonoscopy for screening for colon cancer.
  • RESULTS: Both levels were significantly elevated in patients with adenomas as compared with patients without any neoplastic lesion (TC 207.6+/-29.5 vs 199.5+/-34.3, n=4883, P<0.001; TG 135.0+/-82.2 vs 108.7+/-71.5, n=4874, P<0.001).
  • The difference was significant in patients with tubular adenoma but not in those with villous or serrated adenoma.
  • The level of TG in patients with invasive carcinoma did not show a significant elevation from that in patients with adenoma.
  • These findings suggest that hypertriglyceridemia is an independent risk factor for colonic adenoma in men.
  • [MeSH-major] Adenoma / blood. Adenoma / etiology. Colorectal Neoplasms / blood. Colorectal Neoplasms / etiology. Hypertriglyceridemia / complications

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Triglycerides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 2000;37(1):19-26 [10965515.001]
  • [Cites] Int J Epidemiol. 1998 Oct;27(5):794-8 [9839735.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):412-8 [12750235.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6090-5 [14522940.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):960-4 [14611672.001]
  • [Cites] Cancer. 1977 Jun;39(6):2533-9 [872053.001]
  • [Cites] Cancer Res. 1981 Sep;41(9 Pt 2):3700-5 [6266660.001]
  • [Cites] J Chronic Dis. 1982;35(5):313-20 [7068807.001]
  • [Cites] JAMA. 1986 Jan 17;255(3):365-7 [3941515.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1634-8 [3785334.001]
  • [Cites] Br J Cancer. 1987 Oct;56(4):451-4 [3689662.001]
  • [Cites] Am J Clin Nutr. 1988 Feb;47(2):312-7 [3341261.001]
  • [Cites] Hematol Oncol Clin North Am. 1989 Mar;3(1):35-63 [2537285.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):883-8 [1735079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):687-95 [7881343.001]
  • [Cites] Cancer Causes Control. 1995 Mar;6(2):164-79 [7749056.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1033-8 [7576987.001]
  • [Cites] Scand J Gastroenterol. 1997 Feb;32(2):162-8 [9051877.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1679-84 [9771941.001]
  • [Cites] Climacteric. 2002 Mar;5(1):3-14 [11974557.001]
  • (PMID = 16534881.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ PMC4124439
  •  go-up   go-down


59. García-Faroldi G, Sánchez-Jiménez F, Fajardo I: The polyamine and histamine metabolic interplay in cancer and chronic inflammation. Curr Opin Clin Nutr Metab Care; 2009 Jan;12(1):59-65
Hazardous Substances Data Bank. HISTAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: The most recent and relevant findings that might reflect a link between the polyamines/histamine metabolic interplay and the development of cancer and chronic inflammation-related diseases include: the observation that histamine catabolism is downregulated in the colonic mucosa of patients with colonic adenoma; the finding that some polyamine and histamine-related metabolites are different between a breast cancer cell line and a reference mammary epithelial cell line; and the demonstration of the critical role that mast cells (a cell type in which the polyamine/histamine metabolic interplay has been confirmed) play in the development of pancreatic tumors.
  • There is still, however, a lack of specific studies elucidating the exact contribution of the polyamine/histamine metabolic interplay in these clinical settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057189.001).
  • [ISSN] 1473-6519
  • [Journal-full-title] Current opinion in clinical nutrition and metabolic care
  • [ISO-abbreviation] Curr Opin Clin Nutr Metab Care
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Polyamines; 7LP2MPO46S / S-Adenosylmethionine; 820484N8I3 / Histamine
  • [Number-of-references] 64
  •  go-up   go-down


60. Abramson SB, Greenberg JD: Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction? Nat Clin Pract Rheumatol; 2008 Apr;4(4):182-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An increased risk of MI was found in four RCTs of NSAID use in colonic adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Rheum Dis. 2007 Oct;66(10):1296-304 [17344246.001]
  • (PMID = 18285763.001).
  • [ISSN] 1745-8390
  • [Journal-full-title] Nature clinical practice. Rheumatology
  • [ISO-abbreviation] Nat Clin Pract Rheumatol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


62. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL: Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis; 2007 Oct;66(10):1296-304
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.
  • OBJECTIVE: The comparative risk of myocardial infarction (MI) with cyclo-oxygenase-2-specific drugs and traditional non-steroidal anti-inflammatory drugs (NSAIDs) was determined.
  • METHODS: The results of studies of a suitable size in colonic adenoma and arthritis-that had been published in English and from which crude data about MIs could be extracted-were evaluated.
  • Four RCTs of NSAIDs in colonic adenoma (6000 patients) showed an increased risk of MI (RR 2.68; 95% CI 1.43 to 5.01).
  • Fourteen RCTs in arthritis (45 425 patients) showed more MIs with cyclo-oxygenase-2-specific drugs (Peto OR 1.6; 95% CI 1.1 to 2.4), but fewer serious upper gastrointestinal events (Peto OR 0.40; 95% CI 0.31 to 0.53).
  • CONCLUSION: The overall risk of MI with NSAIDs and cyclo-oxygenase-2-specific drugs was small; rofecoxib showed the highest risk.
  • There was an increased MI risk with cyclo-oxygenase-2-specific drugs compared with NSAIDs, but less serious upper gastrointestinal toxicity.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Myocardial Infarction / chemically induced
  • [MeSH-minor] Adenoma / drug therapy. Arthritis / drug therapy. Colonic Neoplasms / drug therapy. Cyclooxygenase 2 Inhibitors / adverse effects. Gastrointestinal Diseases / chemically induced. Humans. Randomized Controlled Trials as Topic. Research Design. Risk Assessment

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 2004 May;31(5):951-6 [15124256.001]
  • [Cites] BMC Fam Pract. 2002 May 22;3:10 [12033987.001]
  • [Cites] Curr Med Res Opin. 2004 May;20(5):651-8 [15140330.001]
  • [Cites] Circulation. 2004 Jun 22;109(24):3000-6 [15197149.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul 1;20(1):51-63 [15225171.001]
  • [Cites] Ann Rheum Dis. 2004 Aug;63(8):931-9 [15082468.001]
  • [Cites] Lancet. 2004 Aug 21-27;364(9435):639-40 [15325809.001]
  • [Cites] Lancet. 2004 Aug 21-27;364(9435):675-84 [15325832.001]
  • [Cites] Arthritis Rheum. 2004 Aug 15;51(4):549-57 [15334426.001]
  • [Cites] Tob Control. 2004 Sep;13(3):244-50 [15333879.001]
  • [Cites] J Rheumatol. 2004 Sep;31(9):1804-10 [15338504.001]
  • [Cites] Ann Rheum Dis. 2004 Nov;63(11):1419-26 [15020310.001]
  • [Cites] Gastroenterology. 2004 Oct;127(4):1038-43 [15480981.001]
  • [Cites] Clin Exp Rheumatol. 2004 Sep-Oct;22(5):589-96 [15485012.001]
  • [Cites] BMJ. 2004 Oct 16;329(7471):868-9 [15485939.001]
  • [Cites] Lancet. 1995 Dec 16;346(8990):1629 [7500770.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] BMJ. 1998 Jan 10;316(7125):140-4 [9462324.001]
  • [Cites] J Pain. 2004 Nov;5(9):511-20 [15556830.001]
  • [Cites] Lancet. 2004 Dec 4-10;364(9450):2021-9 [15582059.001]
  • [Cites] Ann Intern Med. 2005 Feb 1;142(3):157-64 [15684203.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):402-11 [15693010.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):475-81 [15705456.001]
  • [Cites] JAMA. 2006 Oct 4;296(13):1633-44 [16968831.001]
  • [Cites] Lancet. 2006 Nov 18;368(9549):1771-81 [17113426.001]
  • [Cites] Arch Fam Med. 2000 Nov-Dec;9(10):1124-34 [11115219.001]
  • [Cites] Arthritis Rheum. 2001 Jan;44(1):180-5 [11212158.001]
  • [Cites] Scand J Rheumatol. 2001;30(1):11-8 [11252686.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):1019-27 [11316141.001]
  • [Cites] Am J Manag Care. 2001 Jun;7(6):609-16 [11439734.001]
  • [Cites] Circulation. 2001 Nov 6;104(19):2280-8 [11696466.001]
  • [Cites] J Pharm Pharmacol. 2001 Dec;53(12):1679-85 [11804398.001]
  • [Cites] Lancet. 2002 Jan 12;359(9301):118-23 [11809254.001]
  • [Cites] Osteoarthritis Cartilage. 2002 Apr;10(4):290-6 [11950252.001]
  • [Cites] Curr Med Res Opin. 2002;18(2):49-58 [12017209.001]
  • [Cites] Arch Intern Med. 2002 May 27;162(10):1099-104 [12020178.001]
  • [Cites] Br J Clin Pharmacol. 2002 Sep;54(3):327-32 [12236854.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2433-40 [15334455.001]
  • [Cites] Arch Intern Med. 2002 May 27;162(10):1105-10 [12020179.001]
  • [Cites] Arch Intern Med. 2002 May 27;162(10):1111-5 [12020180.001]
  • [Cites] BMJ. 2002 Jun 22;324(7352):1488-92 [12077033.001]
  • [Cites] J Fam Pract. 2002 Jun;51(6):530-7 [12100776.001]
  • [Cites] J Rheumatol. 2002 Aug;29(8):1623-30 [12180720.001]
  • [Cites] Rheumatology (Oxford). 2002 Sep;41(9):1008-16 [12209034.001]
  • [Cites] Rheumatology (Oxford). 2002 Sep;41(9):1052-61 [12209041.001]
  • [Cites] BMJ. 2002 Sep 21;325(7365):619 [12242171.001]
  • [Cites] Scand J Rheumatol. 2002;31(4):230-8 [12369656.001]
  • [Cites] Lancet. 2002 Oct 5;360(9339):1071-3 [12383990.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):481-6 [12588209.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] Osteoarthritis Cartilage. 2005 Mar;13(3):206-10 [15727886.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):64-77 [15763607.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Ann Intern Med. 2005 Apr 5;142(7):481-9 [15809459.001]
  • [Cites] Mayo Clin Proc. 2005 Apr;80(4):470-9 [15819283.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1205-15 [15818702.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1043-50 [15842577.001]
  • [Cites] Arch Intern Med. 2005 May 9;165(9):978-84 [15883235.001]
  • [Cites] Arthritis Res Ther. 2005;7(3):R644-65 [15899051.001]
  • [Cites] Curr Med Res Opin. 2005 Apr;21(4):517-26 [15899100.001]
  • [Cites] BMJ. 2005 Jun 11;330(7504):1366 [15947398.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2576-8 [15972862.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2578-80 [15972863.001]
  • [Cites] Pharmacotherapy. 2005 Apr;25(4):503-10 [15977911.001]
  • [Cites] Drug Saf. 2005;28(9):803-16 [16119973.001]
  • [Cites] Clin Ther. 2005 Aug;27(8):1196-214 [16199245.001]
  • [Cites] J R Soc Med. 2006 Mar;99(3):132-40 [16508052.001]
  • [Cites] Circulation. 2006 Mar 28;113(12):1578-87 [16534006.001]
  • [Cites] Circulation. 2006 Apr 25;113(16):1950-7 [16618816.001]
  • [Cites] Arthritis Rheum. 2006 May;54(5):1378-89 [16645966.001]
  • [Cites] BMJ. 2006 Jun 3;332(7553):1302-8 [16740558.001]
  • [Cites] Eur Heart J. 2006 Jul;27(14):1657-63 [16731535.001]
  • [Cites] JAMA. 2006 Oct 4;296(13):1653-6 [16968830.001]
  • [Cites] Clin Ther. 1999 Oct;21(10):1688-702 [10566565.001]
  • [Cites] JAMA. 1999 Nov 24;282(20):1921-8 [10580457.001]
  • [Cites] Lancet. 1999 Dec 18-25;354(9196):2106-11 [10609815.001]
  • [Cites] Arthritis Rheum. 2000 Feb;43(2):370-7 [10693877.001]
  • [Cites] Arthritis Rheum. 2000 May;43(5):978-87 [10817549.001]
  • [Cites] Epidemiology. 2000 Jul;11(4):382-7 [10874543.001]
  • [Cites] Arch Intern Med. 2000 Jun 26;160(12):1781-7 [10871971.001]
  • [Cites] JAMA. 2000 Sep 13;284(10):1247-55 [10979111.001]
  • [Cites] Rheumatology (Oxford). 2000 Oct;39(10):1095-101 [11035129.001]
  • [Cites] N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528 [11087881.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):795-806 [12755551.001]
  • [Cites] Am J Gastroenterol. 2003 Aug;98(8):1725-33 [12907325.001]
  • [Cites] Am J Cardiol. 2003 Aug 15;92(4):411-8 [12914871.001]
  • [Cites] J Clin Epidemiol. 2003 Aug;56(8):796-801 [12954473.001]
  • [Cites] Rheumatology (Oxford). 2003 Oct;42(10):1207-15 [12810937.001]
  • [Cites] Ann Intern Med. 2003 Oct 7;139(7):539-46 [14530224.001]
  • [Cites] Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii53-9 [14585918.001]
  • [Cites] Arthritis Rheum. 2003 Nov;48(11):3102-11 [14613272.001]
  • [Cites] Curr Med Res Opin. 2003;19(8):725-36 [14687444.001]
  • [Cites] Arthritis Rheum. 2004 Feb;50(2):598-606 [14872504.001]
  • [Cites] J Am Coll Cardiol. 2004 Mar 17;43(6):985-90 [15028354.001]
  • [Cites] J Am Geriatr Soc. 2004 May;52(5):666-74 [15086644.001]
  • [Cites] Am J Med. 2004 May 1;116(9):621-9 [15093759.001]
  • [Cites] Arch Intern Med. 2004 Apr 26;164(8):852-6 [15111370.001]
  • [Cites] Circulation. 2004 May 4;109(17):2068-73 [15096449.001]
  • [CommentIn] Nat Clin Pract Rheumatol. 2008 Apr;4(4):182-3 [18285763.001]
  • (PMID = 17344246.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors
  • [Number-of-references] 115
  • [Other-IDs] NLM/ PMC1994282
  •  go-up   go-down


63. Micheletto G, Sciannamea I, Zanoni A, Panizzo V, Rubino B, Danelli P: [Intestinal neuroendocrine tumor. Case report and review of the literature]. Ann Ital Chir; 2009 Jul-Aug;80(4):319-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Symptoms are non specific; the most common are abdominal pain, nausea and vomiting, weight loss and gastrointestinal (GI) blood loss.
  • Here we report a case of a 73-year-old male with an adenomatous colonic polyp, not suitable of endoscopic treatment, and a synchronous carcinoid of small intestine discovered during surgical procedure.
  • [MeSH-major] Adenoma. Carcinoid Tumor. Colonic Polyps. Ileal Neoplasms. Neoplasms, Multiple Primary. Sigmoid Neoplasms


64. Lee H, Kim JH, Yang SY, Kong J, Oh M, Jeong DH, Chung JI, Bae KB, Shin JY, Hong KH, Choi I: Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. J Cancer Res Clin Oncol; 2010 Sep;136(9):1445-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients.
  • PURPOSE: To associate the global gene expression of B7/CD28 family transcripts with pathologic features of colon cancer, we determined the B7/CD28 family transcripts in peripheral blood mononuclear cells (PBMCs) from normal subjects and patients with adenomatous polyps and colon cancer, and correlated the results with pathologic features of colon cancer.
  • METHODS: PBMCs from age-matched normal subjects and patients with adenomatous polyps and colon cancer were analyzed for peripheral blood transcripts (PBTs) of B7/CD28 family using real-time PCR.
  • Differences in expression levels of B7/CD28 PBTs across all cancer stages and between colon cancer patients with or without microscopic lymphovascular invasion (LVI) were analyzed.
  • RESULTS: The results showed a significant upregulation of PBTs of co-inhibitory molecules such as B7-H3 and PD-1 and a significant PBT downregulation of co-stimulatory molecules including CD28 and ICOS in colon cancer patients.
  • In addition, the ratios of PBT expression of CD28 family to B7 family such as CTLA-4 to B7-H2 and PD-1 to B7-H2 were significantly higher in colon cancer patients with microscopic LVI than in those without LVI (P = 0.001 and P = 0.016, respectively).
  • CONCLUSIONS: Our results suggest that B7/CD28 family PBTs may serve as valuable markers reflecting the pathological features of colon cancer.
  • [MeSH-major] Antigens, CD28 / genetics. Antigens, CD80 / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Leukocytes, Mononuclear / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140740.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD28; 0 / Antigens, CD80
  •  go-up   go-down


65. Loffeld SM, Loffeld RJ: Colorectal cancer and adenomas are rare in individuals of Turkish descent living in the Zaanstreek region in the Netherlands. J Cancer Res Clin Oncol; 2010 Sep;136(9):1439-43
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer and adenomas are rare in individuals of Turkish descent living in the Zaanstreek region in the Netherlands.
  • Screening and detection of its precursor lesion, the adenoma could prevent development of colorectal cancer.
  • AIM: To evaluate the prevalence of colorectal cancer and adenoma in patients living in the Zaanstreek region, the Netherlands, and correlate these findings with ethnicity.
  • MATERIALS AND METHODS: All patients undergoing endoscopy of the colon and rectum during a period of 16 consecutive years in whom colorectal cancer and/or a polyp were diagnosed, were included in this study.
  • A total of 2,744 patients had one or more polyp(s) during endoscopy.
  • CONCLUSION: Colorectal cancer and colonic adenoma are rare in patients of Turkish descent living in the Zaanstreek region, the Netherlands.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Cancer. 2009 May 1;115(9):1967-76 [19235249.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):287-92 [14639617.001]
  • [Cites] Dis Esophagus. 2004;17(1):87-90 [15209748.001]
  • [Cites] Eur J Epidemiol. 1992 Nov;8(6):845-50 [1294390.001]
  • [Cites] Arch Fam Med. 1995 Oct;4(10):849-56 [7551132.001]
  • [Cites] Colorectal Dis. 2005 Nov;7(6):559-62 [16232235.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2665-72 [16929492.001]
  • [Cites] Am J Clin Nutr. 2007 Dec;86(6):1754-64 [18065596.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2106-14 [18183593.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):22-7 [18386236.001]
  • [Cites] J Natl Med Assoc. 2008 Dec;100(12):1441-4 [19110912.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):259-70 [19109815.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):419-27 [19109819.001]
  • [Cites] J Nutr. 2009 Feb;139(2):340-4 [19091801.001]
  • [Cites] Genet Mol Res. 2009;8(1):64-75 [19283674.001]
  • [Cites] Am J Epidemiol. 2002 Jun 15;155(12):1104-13 [12048224.001]
  • (PMID = 20140623.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2908754
  •  go-up   go-down


66. Lü B, Xu J, Zhu Y, Zhang H, Lai M: Systemic analysis of the differential gene expression profile in a colonic adenoma-normal SSH library. Clin Chim Acta; 2007 Mar;378(1-2):42-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic analysis of the differential gene expression profile in a colonic adenoma-normal SSH library.
  • BACKGROUND: The discovery of differentially expressed genes of colonic adenoma minus normal mucosa enables the understanding of early molecular events in colorectal carcinogenesis.
  • In our previous study, we have developed an adenoma minus normal mucosa suppression subtractive hybridization (SSH) library and identified 109 differentially expressed clones.
  • Realtime quantitative RT-PCR (Q-PCR) was applied to detect the expression of 14-3-3 zeta, REG4 and 6 ribosomal protein genes (RPS2, RPS12, RPS27A, RPL5, RPL7a and RPL10a) in 14 adenomas (8 with concurrent cancers) and 44 colorectal adenocarcinomas with paired normal mucosa.
  • REG4 was significantly upregulated in colorectal adenomas (medium fold: 1.676, p<0.05, Wilcoxon test) and 14-3-3 zeta in cancers (medium fold: 1.202, p<0.01, Wilcoxon test), as compared with those of paired normal mucosa.
  • However, all ribosomal protein genes were not significantly overexpressed in colorectal adenomas or cancers.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Gene Expression Profiling. Gene Library. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184759.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lectins, C-Type; 0 / REG4 protein, human
  •  go-up   go-down


67. Ransohoff DF, Martin C, Wiggins WS, Hitt BA, Keku TO, Galanko JA, Sandler RS: Assessment of serum proteomics to detect large colon adenomas. Cancer Epidemiol Biomarkers Prev; 2008 Aug;17(8):2188-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of serum proteomics to detect large colon adenomas.
  • A noninvasive blood test that could reliably detect early colorectal cancer or large adenomas would provide an important advance in colon cancer screening.
  • The purpose of this study was to determine whether a serum proteomics assay could discriminate between persons with and without a large (> or =1 cm) colon adenoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1536-44 [16570345.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] BMC Cancer. 2006;6:258 [17076885.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6985-8 [17145818.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7347-52 [17189406.001]
  • [Cites] Expert Opin Ther Targets. 2007 Feb;11(2):235-44 [17227237.001]
  • [Cites] J Proteome Res. 2007 Feb;6(2):571-81 [17269714.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1770-7 [12454832.001]
  • [Cites] J Surg Oncol. 2003 Aug;83(4):222-6 [12884234.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):309-14 [15057290.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3127-31 [15457557.001]
  • [Cites] Gastroenterology. 1987 Nov;93(5):1009-13 [3653628.001]
  • [Cites] Int J Biol Markers. 1987 Sep-Dec;2(3):177-83 [2453593.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8380-5 [15623616.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):142-9 [15685197.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1060-72 [16083255.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Biomol Eng. 2006 Jun;23(2-3):119-27 [16542873.001]
  • (PMID = 18708413.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA044684; United States / NCI NIH HHS / CA / R01 CA044684-17; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NCI NIH HHS / CA / 2-R01-CA044684; United States / NIDDK NIH HHS / DK / 5P30DK034987; United States / NCI NIH HHS / CA / CA044684-17; United States / NIDDK NIH HHS / DK / P30 DK034987-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS66903; NLM/ PMC2561171
  •  go-up   go-down


68. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH: Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis; 2005 Apr;26(4):827-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
  • Previous studies indicate that the arachidonic acid-metabolizing enzymes COX-2 and 5-LOX are overexpressed during the process of colonic adenoma formation promoted by cigarette smoke.
  • The aims of the present study were to investigate whether there exists a relationship between COX-2 and 5-LOX, and whether dual inhibition of COX-2 and 5-LOX has an anticarcinogenic effect in the colonic tumorigenesis promoted by cigarette smoke.
  • Results showed that pretreating colon cancer cells with cigarette smoke extract (CSE) promoted colon cancer growth in the nude mouse xenograft model.
  • In an in vitro study, we found that the action of CSE on colon cancer cells was mediated by 5-LOX DNA demethylation.
  • In summary, these results indicate that inhibition of COX-2 may lead to a shunt of arachidonic acid metabolism towards the leukotriene pathway during colonic tumorigenesis promoted by CSE.
  • [MeSH-major] Adenocarcinoma / prevention & control. Colonic Neoplasms / prevention & control. Cyclooxygenase Inhibitors / therapeutic use. Lipoxygenase Inhibitors / therapeutic use. Prostaglandin-Endoperoxide Synthases / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637091.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Lipoxygenase Inhibitors; 0 / RNA, Messenger; 0 / Smoke; 1HGW4DR56D / Leukotriene B4; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


69. Kahveci A, Ari E, Arikan H, Koc M, Tuglular S, Ozener C: Streptococcus bovis bacteremia related to colon adenoma in a chronic hemodialysis patient. Hemodial Int; 2010 Jan;14(1):91-3
MedlinePlus Health Information. consumer health - Streptococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Streptococcus bovis bacteremia related to colon adenoma in a chronic hemodialysis patient.
  • Abstract We report the case of a 54-year-old hemodialysis patient who presented with recurrent fever due to Streptococcus bovis bacteremia related to colonic tubulovillous adenoma.
  • In this paper, we discussed the relation between S. bovis bacteremia, colonic adenomas, and hemodialysis.
  • [MeSH-major] Adenoma / microbiology. Bacteremia / etiology. Colonic Neoplasms / microbiology. Kidney Failure, Chronic / therapy. Renal Dialysis / adverse effects. Streptococcal Infections / pathology. Streptococcus bovis / isolation & purification

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758303.001).
  • [ISSN] 1542-4758
  • [Journal-full-title] Hemodialysis international. International Symposium on Home Hemodialysis
  • [ISO-abbreviation] Hemodial Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


70. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, U.S. Preventive Services Task Force: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med; 2007 Mar 6;146(5):365-75
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DATA SYNTHESIS: Regular use of aspirin reduced the incidence of colonic adenomas in RCTs (relative risk [RR], 0.82 [95% CI, 0.7 to 0.95]), case-control studies (RR, 0.87 [CI, 0.77 to 0.98]), and cohort studies (RR, 0.72 [CI, 0.61 to 0.85]).
  • CONCLUSIONS: Aspirin appears to be effective at reducing the incidence of colonic adenoma and colorectal cancer, especially if used in high doses for more than 10 years.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Colorectal Neoplasms / prevention & control. Primary Prevention
  • [MeSH-minor] Adenoma / prevention & control. Adult. Cardiovascular Diseases / chemically induced. Colonic Polyps / prevention & control. Female. Gastrointestinal Diseases / chemically induced. Humans. Incidence. Male. United States / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ACP J Club. 2007 Jul-Aug;147(1):15-6 [17608380.001]
  • [CommentIn] Gastroenterology. 2007 Aug;133(2):717-8 [17681190.001]
  • [CommentIn] Ann Intern Med. 2007 Nov 6;147(9):674; author reply 674-5 [17975195.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2007 Mar 6;146(5):I35 [17339615.001]
  • (PMID = 17339622.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  • [Number-of-references] 61
  •  go-up   go-down


71. Aminalai A, Rösch T, Aschenbeck J, Mayr M, Drossel R, Schröder A, Scheel M, Treytnar D, Gauger U, Stange G, Simon F, Adler A: Live image processing does not increase adenoma detection rate during colonoscopy: a randomized comparison between FICE and conventional imaging (Berlin Colonoscopy Project 5, BECOP-5). Am J Gastroenterol; 2010 Nov;105(11):2383-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Live image processing does not increase adenoma detection rate during colonoscopy: a randomized comparison between FICE and conventional imaging (Berlin Colonoscopy Project 5, BECOP-5).
  • OBJECTIVES: Fujinon intelligent chromoendoscopy (FICE) is a post-processing imaging technique for increasing contrast of mucosa and mucosal lesions that might lead to improvement in colonic adenoma detection during colonoscopy.
  • This large randomized trial was undertaken to determine whether FICE technology enhances adenoma detection rate (ADR).
  • The primary outcome measure was the ADR (i.e., number of adenomas/total number of patients).
  • RESULTS: There was no difference between the two groups in terms of general ADR (0.28 in both groups), the total number of adenomas (184 vs. 183), or detection of subgroups of adenomas.
  • The rate of identification of hyperplastic polyps was also the same in both groups (127 vs. 121; P=0.67).
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Colonoscopy / methods. Image Processing, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628363.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Buso AG, Rocha HL, Diogo DM, Diogo PM, Diogo-Filho A: Seroprevalence of Helicobacter pylori in patients with colon adenomas in a Brazilian university hospital. Arq Gastroenterol; 2009 Apr-Jun;46(2):97-101
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seroprevalence of Helicobacter pylori in patients with colon adenomas in a Brazilian university hospital.
  • CONTEXT: The association between Helicobacter pylori infection and colon neoplasia has been the subject of recent investigations which have produced controversial results.
  • OBJECTIVE: To evaluate the prevalence of H. pylori infection in patients with colonic adenomas and also in patients whose colonoscopy exams were normal.
  • METHODS: After colonoscopy, the individuals were distributed into two groups: patients with colon adenomas (cases) and patients whose colons were normal (controls).
  • The prevalence of H. pylori in cases and controls according to gender, histological type and location of the colon lesions showed a significant difference only among women (P = 0.03), among patients with tubular adenomas (P = 0.03), and in those with distal adenomas (P = 0.038).
  • CONCLUSION: There is a positive association between H. pylori infection and colonic adenomas.
  • This association is more evident in women, especially for tubular adenomas and distal colonic location.
  • [MeSH-major] Adenoma / microbiology. Colonic Neoplasms / microbiology. Helicobacter Infections / epidemiology. Helicobacter pylori

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578608.001).
  • [ISSN] 1678-4219
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Biomarkers; 0 / Immunoglobulin G
  •  go-up   go-down


73. Steff M, Bourillon A, Frebourg T, Balderi X, Descamps V, Joly P, Piette F, Crestani B, Grandchamp B, Soufir N: [Intra- and interfamilial phenotype variation in Birt-Hogg-Dubé syndrome: Consequences for therapy]. Ann Dermatol Venereol; 2010 Mar;137(3):203-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Variation phénotypique intra- et interfamiliale dans le syndrome de Birt-Hogg-Dubé : conséquences sur la prise en charge.
  • BACKGROUND: Birt-Hogg-Dubé syndrome (BHDS) is an autosomal-dominantly inherited genodermatosis that predisposes to the development of benign hair follicle tumours, lung cysts, kidney tumours, and possibly colonic cancers, due to mutations in the FLCN gene.
  • A cancer genetics consultation was organized and specific tests (dermatological examination, CT scan of chest and abdomen and colonoscopy) were proposed for each BHDS patient.
  • The first proband showed fibrofolliculomas (FF), a history of pneumothorax and colonic adenoma.
  • [MeSH-minor] Adenoma / genetics. Adult. Colonic Neoplasms / genetics. Emphysema / genetics. Female. Hair Diseases / genetics. Humans. Male. Middle Aged. Pedigree. Phenotype. Pneumothorax / genetics. Sequence Analysis, Protein

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Masson SAS.
  • (PMID = 20227563.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / FLCN protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


74. Arslan N, Dehdashti F, Siegel BA: FDG uptake in colonic villous adenomas. Ann Nucl Med; 2005 Jun;19(4):331-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG uptake in colonic villous adenomas.
  • Colonic adenomas constitute 70-80% of all colorectal polyps, and their clinical significance relates primarily to their relationship with colorectal cancer.
  • The malignant potential of the polyps detected by FDG-PET is unknown, as not all the colonic lesions identified by FDG-PET represent colorectal malignancies.
  • The purpose of this study was to investigate the rate of FDG-PET positivity within colonic villous adenomas.
  • A pathology database search was performed to identify all patients diagnosed with colonic villous adenoma between June 1, 1996 and December 1, 2000.
  • Patients with a pathologic diagnosis of colonic villous adenoma and who also had a FDG-PET study up to 1 month before colonoscopy were included in this study.
  • Of more than 4,000 patients, six patients were diagnosed with colonic adenoma on subsequent colonoscopy following FDG-PET study.
  • Based on the pathological findings, these 6 patients had a total of 2 villous and 9 tubulovillous adenomas.
  • Five of the 6 patients showed foci of increased FDG uptake in the region of the colon that corresponded to the villous adenoma(s) detected on colonoscopy, which accounted for a true-positive rate of 83.3% (5/6 subjects).
  • Focal lesions in the colon seen on FDG-PET examinations need to be investigated further, even though some of these will prove to be villous adenomas rather than colorectal carcinomas.
  • Future studies in a larger number of patients are needed to evaluate the relationship of histopathological features of colonic polyps and detectability of these lesions by FDG-PET.
  • [MeSH-major] Adenoma, Villous / radionuclide imaging. Colorectal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097645.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


75. Elphick DA, Tophill PR, Suvarna SK, Riley SA: Flat adenomas in a colonic bladder augmentation patch: cystoscopic removal using an endoscopic mucosal resection technique. Urology; 2008 Jul;72(1):230.e1-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flat adenomas in a colonic bladder augmentation patch: cystoscopic removal using an endoscopic mucosal resection technique.
  • Bladder augmentation using colonic patches is being increasingly performed and a substantial risk of neoplasia in such patches has been reported.
  • We present the case of a 62-year-old man who developed a large flat adenoma in the colonic mucosa of an augmented bladder.
  • The adenoma was indigo-carmine dye sprayed and completely resected via a cystoscope using an endoscopic mucosal resection technique.
  • We discuss how methods used at colonoscopy to detect and remove early neoplastic lesions may readily be employed during colonic patch surveillance at cystoscopy.
  • [MeSH-major] Adenoma / surgery. Colon / transplantation. Cystoscopy. Urinary Bladder / surgery. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308376.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Guz J, Foksinski M, Siomek A, Gackowski D, Rozalski R, Dziaman T, Szpila A, Olinski R: The relationship between 8-oxo-7,8-dihydro-2'-deoxyguanosine level and extent of cytosine methylation in leukocytes DNA of healthy subjects and in patients with colon adenomas and carcinomas. Mutat Res; 2008 Apr 2;640(1-2):170-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between 8-oxo-7,8-dihydro-2'-deoxyguanosine level and extent of cytosine methylation in leukocytes DNA of healthy subjects and in patients with colon adenomas and carcinomas.
  • Therefore, the aim of the present study was to assess a possible link between 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) background level and 5-methylcytosine content in DNA from human leukocytes of healthy subjects (n=105) as well as in patients with colon adenomas (n=39) and carcinomas (n=50).
  • The mean content of 5-methylcytosine was significantly lower, while 8-oxodG level was significantly higher in leukocytes DNA of patients with colon adenomas and carcinomas in comparison with healthy subjects.
  • The mean values for 5-methylcytosine were: 3.59+/-0.173% (healthy subjects), 3.38+/-0.128% (patients with adenomas), 3.40+/-0.208% (colon cancer patients).
  • DNA from affected tissue (colon) suffered from significant, about 10% reduction in cytosine methylation in comparison with leukocytes of the paired subjects.
  • [MeSH-major] 5-Methylcytosine / metabolism. Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. Deoxyguanosine / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281064.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 6R795CQT4H / 5-Methylcytosine; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; 8J337D1HZY / Cytosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


77. Yoshida I, Suzuki A, Vallée M, Matano Y, Masunaga T, Zenda T, Shinozaki K, Okada T: Serum insulin levels and the prevalence of adenomatous and hyperplastic polyps in the proximal colon. Clin Gastroenterol Hepatol; 2006 Oct;4(10):1225-31
MedlinePlus Health Information. consumer health - Diabetes Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum insulin levels and the prevalence of adenomatous and hyperplastic polyps in the proximal colon.
  • BACKGROUND & AIMS: Obesity and diabetes mellitus are associated with an increased incidence of proximal colon cancer.
  • Colonic adenoma that has been reported to be associated with elevated serum insulin levels and subsets of hyperplastic polyps might serve as a precursor of colon cancer.
  • In this study, we sought to determine segment-specific associations between serum insulin levels and the prevalence of adenoma and hyperplastic polyps in the proximal and distal colon.
  • We performed multinomial logistic regression models by using the outcome categories of none (reference), proximal-only, distal-only, and both-segment lesions for the presence of adenoma/hyperplastic polyp with serum insulin, age, gender, lifestyle characteristics, and the presence of other types of lesions as predictors.
  • RESULTS: Overall, serum insulin levels were significantly associated with adenoma (OR, 1.5; 95% CI, 1.1-2.0; P = .005) and borderline associated with hyperplastic polyps (OR, 1.3; 95% CI, 1.0-1.7; P = .075).
  • In multinomial logistic regression models, elevated serum insulin levels were significantly associated with proximal-only adenoma (OR, 1.8; 95% CI, 1.2-2.5; P = .002), both-side hyperplastic polyp (OR, 1.7; 95% CI, 1.1-2.5; P = .015), and proximal-only hyperplastic polyp (OR, 1.5; 95% CI, 1.0-2.1; P = .048) and borderline associated with distal-only adenoma (OR, 1.5; 95% CI, 1.0-2.1; P =.059) but not with distal-only hyperplastic polyp.
  • CONCLUSIONS: Serum insulin levels directly correlate with the presence of adenoma and hyperplastic polyps in the proximal colon and might also less strongly correlate with the presence of distal adenoma.
  • [MeSH-major] Adenomatous Polyposis Coli / blood. Biomarkers, Tumor / blood. Colonic Polyps / blood. Colonic Polyps / epidemiology. Insulin / blood

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Gastroenterol Hepatol. 2007 Jan;5(1):137
  • (PMID = 16979948.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin
  •  go-up   go-down


78. Burn J, Bishop DT, Mecklin JP, Macrae F, Möslein G, Olschwang S, Bisgaard ML, Ramesar R, Eccles D, Maher ER, Bertario L, Jarvinen HJ, Lindblom A, Evans DG, Lubinski J, Morrison PJ, Ho JW, Vasen HF, Side L, Thomas HJ, Scott RJ, Dunlop M, Barker G, Elliott F, Jass JR, Fodde R, Lynch HT, Mathers JC, CAPP2 Investigators: Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med; 2008 Dec 11;359(24):2567-78
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Observational and epidemiologic data indicate that the use of aspirin reduces the risk of colorectal neoplasia; however, the effects of aspirin in the Lynch syndrome (hereditary nonpolyposis colon cancer) are not known.
  • Resistant starch has been associated with an antineoplastic effect on the colon.
  • METHODS: In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome.
  • Over a mean period of 29 months (range, 7 to 74), colonic adenoma or carcinoma developed in 141 participants.
  • Advanced adenomas and colorectal cancers were evenly distributed in the two groups.
  • CONCLUSIONS: The use of aspirin, resistant starch, or both for up to 4 years has no effect on the incidence of colorectal adenoma or carcinoma among carriers of the Lynch syndrome. (Current Controlled Trials number, ISRCTN59521990. )

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854759 for PMID:19073976 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Massachusetts Medical Society
  • [CommentIn] N Engl J Med. 2009 Apr 2;360(14):1462; author reply 1462-3 [19348022.001]
  • [CommentIn] Gastroenterology. 2009 Aug;137(2):730-2 [19563844.001]
  • [CommentIn] N Engl J Med. 2009 Apr 2;360(14):1461-2; author reply 1462-3 [19339729.001]
  • [ErratumIn] N Engl J Med. 2009 Apr 2;360(14):1470
  • (PMID = 19073976.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ISRCTN/ ISRCTN59521990
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / D20173; United Kingdom / Medical Research Council / / G0100496; United Kingdom / Medical Research Council / / MC/ U127527198; United Kingdom / Cancer Research UK / / A4994; United Kingdom / Cancer Research UK / / C1297/A5013; United Kingdom / Cancer Research UK / / C588/A4994
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9005-25-8 / Starch; R16CO5Y76E / Aspirin
  • [Investigator] Adamson P; Armstrong O; Ball J; Baxter L; Birkett A; Boussioutas A; Bradshaw N; Brewer C; Broughton M; Bulman B; Castiglione M; Clarke S; Ching R; Chu C; Coaker J; Cina S; Cook J; Coxhead J; Crawford G; Cummings C; Davies R; Debniak T; de Moncuit C; Drummond S; Ellis T; Farthing K; Fidalgo P; Gallinger S; Gascoyne J; Gilroy J; Goff S; Goldberg P; Goodman S; Harocopos C; Hodgson S; Jeffcoat R; Jeffers L; Jordan S; Killick P; Krauss C; Kristensen J; Langman C; Leite J; Liljegren A; Lindgren G; Lynagh L; Oliani C; Marks C; Miller J; Miles T; Murday V; Perez Segura P; Pietersen E; Platten U; Reed L; Rossi G; Sala P; Sampson J; Schmocker B; Shaw J; Spigelman A; Tempesta A; Toes R; Velthuizen M; Wakelen P; Walpole I; Lynch H; Burn J; Mathers J; Bishop DT; Fodde R; Mecklin JP; Macrae F; Vasen H; Möslein G; Ramesar R; Kerr D; Perkins S; Cuzick J; Faulds Wood L; Steele R; Altman D; Paraskeva C; Atkin W; Hull M
  •  go-up   go-down


79. Lagarde S, Dauphin M, Delmas C, Vitry F, Bouché O, Thiéfin G, Diebold MD, Cadiot G: Increased risk of colonic neoplasia in patients with sporadic duodenal adenoma. Gastroenterol Clin Biol; 2009 May;33(5):441-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of colonic neoplasia in patients with sporadic duodenal adenoma.
  • PATIENTS AND METHODS: Rate of colorectal neoplasia in 29 patients with one or more duodenal adenomas were compared with controls matched for gender and age, but without duodenal adenomas (one case to two controls).
  • Patients with neoplasia of the ampulla, familial adenomatous polyposis or other known hereditary conditions of the digestive tract were excluded.
  • Neoplastic lesions found at colonoscopy were classified as adenomas, advanced adenomas (size > or =10 mm, villous component, high-grade dysplasia), cancers and advanced neoplasia (cancers and advanced adenomas).
  • Colonoscopy showed at least one adenoma in 15 cases (51.7%) and 11 controls (19%) (P=0.0027; OR 1.87, 1.0-3.49), advanced adenomas in four cases (13.8%) and three controls (5.2%) (NS), and colonic adenocarcinoma in three cases (10.3%) and no controls (0%) (P=0.03).
  • CONCLUSION: Although lacking in statistical power, these results confirm that patients with sporadic duodenal adenoma are at high risk of colonic adenoma and advanced neoplasia, warranting systematic colonoscopy.
  • [MeSH-major] Adenoma / epidemiology. Colonic Neoplasms / epidemiology. Duodenal Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278801.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


80. Yamada T, Tamura S, Onishi S, Hiroi M: A comparison of magnifying chromoendoscopy versus histopathology of forceps biopsy specimen in the diagnosis of minute flat adenoma of the colon. Dig Dis Sci; 2009 Sep;54(9):2002-8
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of magnifying chromoendoscopy versus histopathology of forceps biopsy specimen in the diagnosis of minute flat adenoma of the colon.
  • Having noted a discrepancy between endoscopic and histopathological diagnoses in cases of minute adenomas of the colon, a prospective study was designed to clarify which is appropriate, magnifying chromoendoscopy or histopathology of a specimen obtained by biopsy forceps.
  • Comparison of the initial diagnoses between groups A and B showed that a total of 84.6% (88/104) of the lesions were diagnosed to be tubular adenomas histopathologically in group A, compared with 100% (104/104) in group B (P < 0.0001).
  • Results for comparison of the secondary diagnoses between group A and group B showed that 14 of the 16 lesions were diagnosed as tubular adenomas histopathologically.
  • Thereafter, 98.1% (102/104) of the lesions were diagnosed to be tubular adenomas histopathologically in group A (P = 0.4976).
  • In conclusion, high-resolution magnifying chromoendoscopy is an appropriate procedure for the diagnosis of minute adenomas in comparison with histopathology of specimens obtained by biopsy forceps in this prospective study.
  • [MeSH-major] Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Colonoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037726.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Bougatef K, Marrakchi R, Moussa A, Blondeau-Lahely Y, Najjar T, Coulet F, Colas C, Ben Ayed F, Ben Ammar Elgaaied A, Soubrier F: First genetic analysis in Tunisian familial adenomatous polyposis probands. Oncol Rep; 2008 May;19(5):1213-8
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First genetic analysis in Tunisian familial adenomatous polyposis probands.
  • Familial adenomatous polyposis (FAP) is an autosomal dominant inherited disease characterized by the development of hundreds to thousands of adenomatous polyps in colon and rectum.
  • The APC gene (adenomatous polyposis coli) is considered as the major mutated gene in FAP.
  • It has been shown that biallelic germline mutations in the base-excision-repair gene MYH can be responsible for a recessive inheritance of adenomatous polyposis (AP).
  • [MeSH-major] Adenomatous Polyposis Coli / ethnology. Adenomatous Polyposis Coli / genetics. Genetic Predisposition to Disease

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425378.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


82. Lee GE, Park HS, Yun KE, Jun SH, Kim HK, Cho SI, Kim JH: Association between BMI and metabolic syndrome and adenomatous colonic polyps in Korean men. Obesity (Silver Spring); 2008 Jun;16(6):1434-9
MedlinePlus Health Information. consumer health - Metabolic Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between BMI and metabolic syndrome and adenomatous colonic polyps in Korean men.
  • Obesity and insulin resistance are associated with the risk of colon cancer.
  • Adenomatous colonic polyps are precancerous lesions of colon cancer.
  • We investigated whether BMI and the metabolic syndrome are associated with the presence of adenomatous colonic polyps in Korean men.
  • Multiple logistic regression analysis was used to evaluate the association between BMI and the metabolic syndrome and adenomatous polyps.
  • Compared with men in the 1st quintile of the BMI, the adjusted odds ratio (OR) and 95% confidence interval (CI) for adenomatous polyps in men in the 2nd, 3rd, 4th, and 5th quintiles of the BMI were 1.55 (1.10-2.19), 1.57 (1.10-2.24), 1.94 (1.34-2.81), and 1.99 (1.31-3.01), respectively (P for trend <0.0001).
  • Men with triglycerides (TGs) > or = 150 mg/dl were significantly more likely to have adenomatous polyps than were men with TG <150 mg/dl (OR 1.29; 95% CI 1.03-1.62).
  • As a function of the number of metabolic risk factors, the ORs for adenomatous polyps were 1.41 (1.03-1.93), 1.52 (1.08-2.12), 1.46 (1.01-2.12), and 1.77 (1.08-2.90) for 1, 2, 3, and > or = 4 risk factors, respectively (P for trend <0.05).
  • Adenomatous colonic polyps were significantly associated with increased BMI levels.
  • Subjects with even one component of the metabolic syndrome had a significantly higher risk for developing adenomatous polyps compared to those subjects without any component in Korean men.
  • [MeSH-major] Adenomatous Polyps / epidemiology. Body Mass Index. Colonic Polyps / epidemiology. Metabolic Syndrome X / physiopathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18388894.001).
  • [ISSN] 1930-7381
  • [Journal-full-title] Obesity (Silver Spring, Md.)
  • [ISO-abbreviation] Obesity (Silver Spring)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triglycerides
  •  go-up   go-down


83. Tsai IC, Woolf M, Neklason DW, Branford WW, Yost HJ, Burt RW, Virshup DM: Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism. Int J Cancer; 2007 Mar 1;120(5):1005-12
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism.
  • We speculated that mutations in the autoinhibitory domain of CKIdelta/epsilon might upregulate CKIdelta/epsilon activity and hence Wnt signaling and increase the risk of adenomatous polyps and colon cancer.
  • Exons encoding the CKIepsilon and CKIdelta regulatory domains were sequenced from DNA obtained from individuals with adenomatous polyps and a family history of colon cancer unaffected by familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer (HNPCC).
  • A CKIdelta missense mutation, changing a highly conserved residue, Arg324, to His (R324H), was found in an individual with large and multiple polyps diagnosed at a relatively young age.
  • Second, CKIdelta(R324H) is more potent than wildtype CKIdelta in transformation of RKO colon cancer cells.
  • This novel human CKIdelta mutation may alter the physiological role and enhance the transforming ability of CKIdelta through a Wnt/beta-catenin independent mechanism and thereby influence colonic adenoma development.
  • [MeSH-major] Adenomatous Polyps / genetics. Casein Kinase Idelta / genetics. Colonic Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17131344.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-3541; United States / NCI NIH HHS / CA / P01 CA73992; United States / NCI NIH HHS / CA / P30 CA42014; United States / NCI NIH HHS / CA / R01 CA40641; United States / NCI NIH HHS / CA / R01 CA80809
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin; 4QD397987E / Histidine; 94ZLA3W45F / Arginine; EC 2.7.11.1 / Casein Kinase Idelta
  •  go-up   go-down


84. Florek M, Wojtuń S, Gil J: [New possibilities for detection of adenomas of the colon]. Pol Merkur Lekarski; 2009 May;26(155):562-4
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New possibilities for detection of adenomas of the colon].
  • More and more modern diagnostic methods are utilised in detection of colon adenomatous lesions.
  • Currently developed new diagnostics methods can set new standards in detection of colon adenomatous lesions in the future.
  • The study targets to present modern diagnostic methods and their utilisation in detection of various colon adenomatous lesions.
  • [MeSH-major] Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Colonoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606727.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 16
  •  go-up   go-down


85. Kim CS, Kim MC, Cheong HK, Jeong TH: [The association of obesity and left colonic adenomatous polyps in Korean adult men]. J Prev Med Public Health; 2005 Nov;38(4):415-9
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The association of obesity and left colonic adenomatous polyps in Korean adult men].
  • OBJECTIVES: We wanted to evaluate the relationship between obesity and left colonic adenomatous polyps in Korean adult men.
  • RESULTS: There were 99 cases of colonic adenomatous polyps.
  • The BMI and WHR were associated with the adenomatous polyps (odds ratio, 1.81 [95% CI=1.02-3.19] for a BMI > or = 25.0 as compared with a BMI < or = 22.9, odds ratio, 3.94 [95% CI = 1.77-8.77] for a WHR > or = 0.95 as compared with a WHR < or = 0.86).
  • The BMI was not associated with the risk of adenomatous polyps after additional adjustment was made for the WHR, but the association between the WHR and adenomatous polyps was still positive and independent of the BMI (odds ratio, 4.15 [95% CI=1.63-10.59]).
  • CONCLUSIONS: The results support that obesity, and particularly abdominal obesity, can be associated with an increased risk of incurring colonic adenomatous polyps.
  • [MeSH-major] Adenomatous Polyps / etiology. Colonic Polyps / etiology. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358826.001).
  • [ISSN] 1975-8375
  • [Journal-full-title] Journal of preventive medicine and public health = Yebang Ŭihakhoe chi
  • [ISO-abbreviation] J Prev Med Public Health
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


86. Oset P, Jasińska A, Szcześniak P, Orszulak-Michalak D, Talar-Wojnarowska R, Małecka-Panas E: [Analysis of serum gastrin levels in patients with adenomatous polyps of the colon]. Pol Merkur Lekarski; 2009 May;26(155):458-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of serum gastrin levels in patients with adenomatous polyps of the colon].
  • Adenomatous polyps are known risk factor of colon cancer.
  • Gastrin is a peptide hormone involved in the growth of both normal and malignant intestinal tissue, which probably may promote progression through the adenoma-carcinoma sequence.
  • AIM OF OUR STUDY: To assess the association between serum gastrin levels and size, type and localization of colonic adenomas.
  • MATERIAL AND METHODS: The study included 60 patients with adenomatous polyps of the colon and 30 healthy volunteers.
  • RESULTS: We observed higher serum gastrin levels in patients with colonic adenomas compared to control group (59.65 pg/ml vs. 46.89 pg/ml; p < 0.05).
  • There was no association between gastrin levels and size, number, localisation and histologic type of polyps (p > 0.05).
  • CONCLUSION: Despite of elevated serum levels in patients with colonic adenomas we did not observe the association between gastrin levels and size, grade of dysplasia and histologic type of polyps.
  • The exact role of hipergastrinemia in process of colon carcinogenesis remains to be determined.
  • [MeSH-major] Adenomatous Polyps / blood. Gastrins / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606697.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


87. Galamb O, Gyorffy B, Sipos F, Spisák S, Németh AM, Miheller P, Dinya E, Molnár B, Tulassay Z: [Identification of colorectal cancer, adenoma, and inflammatory bowel disease specific gene expression patterns using whole genomic oligonucleotide microarray system]. Orv Hetil; 2007 Nov 4;148(44):2067-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of colorectal cancer, adenoma, and inflammatory bowel disease specific gene expression patterns using whole genomic oligonucleotide microarray system].
  • [Transliterated title] Vastagbél-adenoma, vastagbélrák és IBD-specifikus génexpressziós mintázatok meghatározása teljes genomszintu oligonukleotid microarray-rendszerrel.
  • BACKGROUND: Discrimination and classification of colorectal diseases (adenoma, colorectal cancer, inflammatory bowel disease) using biopsy samples and expression microarrays, has not been solved yet, nevertheless, it can contribute to the understanding of the colonic diseases.
  • METHODS: Total ribonucleic acid was extracted, amplified and biotinylated from frozen colonic biopsies of 15 patients with colorectal cancer, 15 with adenoma, 14 with inflammatory bowel disease and 8 normal controls.
  • RESULTS: Top validated genes included CD44 antigen, met proto-oncogene, chemokine ligand-12, ADAM-like decysin-1 and ATP-binding casette-A8 genes in adenoma; collagen IValpha1, lipocalin-2, calumenin, aquaporin-8 genes in colorectal cancer; and lipocalin-2, ubiquitin D and interferon induced transmembrane protein 2 genes in inflammatory bowel disease.
  • [MeSH-major] Adenoma / diagnosis. Colorectal Neoplasms / diagnosis. Gene Expression Profiling. Inflammatory Bowel Diseases / diagnosis. Oligonucleotide Array Sequence Analysis


88. Jurek D, Fleckl E, Marian B: Bile acid induced gene expression in LT97 colonic adenoma cells. Food Chem Toxicol; 2005 Jan;43(1):87-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile acid induced gene expression in LT97 colonic adenoma cells.
  • LT97 human colonic adenoma cells reflecting early premalignant genotype and growth characteristics have been posed to tumor promoting bile acids in order to identify marker genes that permit identification of tumor promoters in vitro.
  • Transient induction of c-fos was seen with the non-promoting taurodesoxycholate (TDOC) as well as DOC, however extended induction at 3 h was only achieved by DOC and CDC reaching 3-6-fold as compared to the control.
  • Stimulation of COX-2 expression was completely specific for the tumor promoting analogs DOC and CDC.
  • Expression of VEGF was stimulated 4-5-fold in the tumor promoter (DOC and CDC) groups and about 2-fold in the non-promoting controls TDOC and GCDC.
  • At later times the tumor promoter specific difference was lost.
  • Our results show that all three genes are modulated in a tumor promoter dependent way and that their upregulation in LT97 adenoma cells can be used for in vitro testing of colon tumor promoters and chemopreventive compounds.
  • [MeSH-major] Adenoma / metabolism. Bile Acids and Salts / pharmacology. Biomarkers, Tumor / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / drug effects

  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582199.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-fos; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 005990WHZZ / Deoxycholic Acid; 0GEI24LG0J / Chenodeoxycholic Acid; 516-50-7 / Taurodeoxycholic Acid; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


89. Benes Z, Antos Z: Optical biopsy system distinguishing between hyperplastic and adenomatous polyps in the colon during colonoscopy. Anticancer Res; 2009 Nov;29(11):4737-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical biopsy system distinguishing between hyperplastic and adenomatous polyps in the colon during colonoscopy.
  • BACKGROUND: It has been established that the removal of adenomatous colon polyps drastically reduces the incidence of colorectal cancer (CRC), but polypectomy is not without risk.
  • The aim was to determine the correlation between the results of an optical biopsy system and the histopathology report of the physical biopsy specimens of the same polyps removed at colonoscopy.
  • PATIENTS AND METHODS: Paired optical and physical biopsies were performed on 55 polyps with complete polypectomy of the same tissue.
  • RESULTS: Fifty-three adenomatous polyps and two hyperplastic polyps were identified by the hospital pathologist.
  • The optical biopsy system identified 52 polyps as suspect (adenomatous) and 2 as non-suspect (hyperplastic).
  • One villous adenoma could not be optically analyzed due to friability.
  • CONCLUSION: The WavSTAT Optical Biopsy System provides accurate information to the gastroenterologist to assist in distinguishing between hyperplastic and adenomatous polyps.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Colon / pathology
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy / methods. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonoscopy / methods. Diagnosis, Differential. Humans. Hyperplasia / diagnosis. Middle Aged. Optics and Photonics / methods. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032428.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


90. Jung WT, Li MS, Goel A, Boland CR: JC virus T-antigen expression in sporadic adenomatous polyps of the colon. Cancer; 2008 Mar 1;112(5):1028-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JC virus T-antigen expression in sporadic adenomatous polyps of the colon.
  • The hypothesis that JCV DNA sequences and T-antigen (T-Ag) expression may be present in adenomatous polyps of the colon was tested.
  • METHODS: DNA was extracted from 74 paraffin-embedded adenomatous polyps.
  • Immunohistochemical staining was performed to localize T-Ag expression in the adenomas using a monoclonal antibody.
  • RESULTS: JCV T-Ag sequences were found in 82% (61 of 74) of adenomas, and T-Ag protein was expressed in 16% (12 of 74) of these polyps.
  • The T-Ag staining was localized exclusively in the nuclei of adenoma cells, but never in the cytoplasm or the adjacent nonneoplastic cells.
  • The prevalence of MSI-H and non-MSI-H (MSI-L/MSS) in adenomatous polyps was 9.5% (7 of 74) and 90.5% (67 of 74), respectively.
  • Among the 61 adenomas that harbored JCV sequences, 8% (5 of 61) were MSI-H, and similarly among 12 adenomatous polyps expressing T-Ag protein 8% (1 of 12) of the adenomatous polyps were MSI-H.
  • CONCLUSIONS: JCV T-Ag DNA sequences are frequently present in adenomatous polyps of the colon, and T-Ag is expressed specifically in the nuclei of these premalignant lesions.
  • This study indicates that JCV T-Ag is present in the early stage of colonic carcinogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(17):6233-43 [10938100.001]
  • [Cites] Virology. 2000 Aug 15;274(1):165-78 [10936097.001]
  • [Cites] Int J Colorectal Dis. 2000 Aug;15(4):189-96 [11008717.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1228-35 [11054380.001]
  • [Cites] J Virol. 2001 Feb;75(4):1996-2001 [11160700.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4287-93 [11358858.001]
  • [Cites] Oncogene. 2001 Aug 9;20(35):4864-70 [11521197.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Gut. 2002 Mar;50(3):382-6 [11839719.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):267-73 [11854388.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7093-101 [12460931.001]
  • [Cites] J Neurovirol. 2002 Dec;8 Suppl 2:138-47 [12491166.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1499-504 [12771419.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5181-91 [12910255.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):42-8 [14699485.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Microbiol Immunol. 1982;26(11):1057-64 [6300615.001]
  • [Cites] J Virol. 1984 Aug;51(2):458-69 [6086957.001]
  • [Cites] J Virol. 1989 Feb;63(2):863-72 [2536108.001]
  • [Cites] J Virol. 1990 Mar;64(3):1353-6 [2154613.001]
  • [Cites] J Virol. 1992 Jul;66(7):3979-85 [1318392.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1645-8 [8137274.001]
  • [Cites] Int J Mol Med. 1998 Apr;1(4):647-55 [9852278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7484-9 [10377441.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Dec;20(12):1920-6 [16336454.001]
  • [Cites] Gut. 2006 May;55(5):695-702 [16354798.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1950-61 [16762618.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):481-8 [16795066.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Nov;63(11):1124-30 [15581180.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):516-27 [15630684.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):86-91 [15690663.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1143-9 [15842591.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):1079-85 [15868949.001]
  • [Cites] Gut. 2005 Sep;54(9):1321-31 [16099799.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):723-30 [16021515.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • (PMID = 18205186.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098572-05; United States / NCI NIH HHS / CA / R01 CA098572; United States / NCI NIH HHS / CA / R01 CA 98572; United States / NCI NIH HHS / CA / R01 CA098572-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS187525; NLM/ PMC2855201
  •  go-up   go-down


91. Zinzindohoué F, Samama G: [Colonic diverticulosis: which patients need surgery?]. Rev Prat; 2009 Jan 20;59(1):16-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic diverticulosis: which patients need surgery?].
  • A two-months delay between symptoms and surgery is suitable, and permits to perform preoperatively a colonoscopy in a safe condition to rule out concomitant adenoma or colonic cancer.
  • There is no randomised trial of open versus laparoscopic colectomy in this specific indication.
  • As the lesions of resected colon became more severe due to restricted indications, laparoscopic approach will require more surgical skill and conversion rate might increase.
  • [MeSH-major] Colectomy / methods. Diverticulosis, Colonic / surgery. Patient Selection
  • [MeSH-minor] Age of Onset. Diverticulum, Colon / pathology. Diverticulum, Colon / surgery. Hemorrhage / surgery. Humans. Incidence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253874.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 20
  •  go-up   go-down


92. Wolfsen HC: Endoluminal therapy for esophageal disease: an introduction. Gastrointest Endosc Clin N Am; 2010 Jan;20(1):1-10, v

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two premalignant conditions, BE and colon adenoma, are compared, including their progression to esophageal adenocarcinoma and colon and rectal carcinoma, respectively.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Adenoma / pathology. Carcinoma / etiology. Carcinoma / prevention & control. Colonic Neoplasms / etiology. Colonic Neoplasms / pathology. Colonic Neoplasms / prevention & control. Disease Progression. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Humans. Precancerous Conditions / etiology. Precancerous Conditions / pathology. Precancerous Conditions / prevention & control. Rectal Neoplasms / etiology. Rectal Neoplasms / prevention & control. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951790.001).
  • [ISSN] 1558-1950
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 84
  •  go-up   go-down


93. Loungnarath R, Mutch MG, Birnbaum EH, Read TE, Fleshman JW: Laparoscopic colectomy using cancer principles is appropriate for colonoscopically unresectable adenomas of the colon. Dis Colon Rectum; 2010 Jul;53(7):1017-22
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy using cancer principles is appropriate for colonoscopically unresectable adenomas of the colon.
  • PURPOSE: This study was undertaken to determine the risks of cancer in unresectable polyps and to compare the short-term outcome of laparoscopic colectomy with that of open colectomy for benign polyps.
  • METHODS: A retrospective review of all patients (n = 165) undergoing colectomy for an adenoma unresectable at colonoscopy was performed on patients collected in a prospective database.
  • CONCLUSION: Laparoscopic colectomy for polyps unresectable at colonoscopy is safe.
  • Oncologic resection of the colon should be performed for all colonoscopically unresectable polyps due to the risk of cancer.
  • [MeSH-major] Adenoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Colonoscopy / contraindications. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551753.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Ma YM, Wu BP, Xia OD: [Expression and significance of interferon-inducible transmembrane protein-1 gene in Peutz-Jeghers syndrome]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):541-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To detect the mRNA and protein expression of interferon-inducible transmembrane protein-1 (IFITM1) in Peutz-Jeghers syndrome (PJS) and investigate the role of IFITM1 in the occurrence, development and carcinogenesis of PJS polyps.
  • METHODS: Reverse transcription-PCR was employed to detect the mRNA expression of IFITM1 in 16 PJS polyp samples, adenomatous polyp tissues, colon adenocarcinoma samples, and normal intestinal mucosal tissues.
  • RESULTS: The IFITM1 mRNA expression was detected in all these tissues, and the expression intensity increased in the order of normal intestinal mucosa, PJS polyp, adenomatous polyp, and colon adenocarcinoma (F=92.704, P=0.000).
  • CONCLUSION: The expression level of IFITM1 is associated with the progression of the carcinogenetic process in PJS polyp, and can be used as a sensitive biomarker for diagnosis and prognostic evaluation of PJS.

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304549.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / leu-13 antigen
  •  go-up   go-down


95. Luo F, Ye H, Hamoudi R, Dong G, Zhang W, Patek CE, Poulogiannis G, Arends MJ: K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation. J Pathol; 2010 Apr;220(5):542-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation.
  • The present study evaluated whether K-ras 4A expression can suppress colonic adenoma development in the absence of its oncogenic allele.
  • Mice with homozygous targeted deletions of K-ras exon 4A (K-ras(tmDelta4A/tmDelta4A)) that can express the K-ras 4B isoform only, along with heterozygous K-ras(tmDelta4A/+) and wild-type mice, were given ten weekly 1,2-dimethylhydrazine (DMH) treatments to induce colonic adenomas.
  • There was a significant increase in both the number and the size of colonic adenomas in DMH-treated K-ras(tmDelta4A/tmDelta4A) mice, with reduced survival, compared with heterozygous and wild-type mice.
  • Lack of expression of K-ras 4A transcripts was confirmed, whereas the relative expression levels of K-ras 4B transcripts were significantly increased in the adenomas of K-ras(tmDelta4A/tmDelta4A) mice compared with K-ras(tmDelta4A/+) and wild-type mice.
  • Immunohistochemical studies showed that adenomas of K-ras(tmDelta4A/tmDelta4A) mice had significantly increased cell proliferation and significantly decreased apoptosis with evidence of activation of MapKinase and Akt pathways, with increased phospho-Erk1/2 and both phospho-Akt-Thr308 and phospho-Akt-Ser473 immunostaining, compared with adenomas from K-ras(tmDelta4A/+) and wild-type mice.
  • In conclusion, following DMH treatment, K-ras exon 4A deletion promoted increased number and size of colonic adenomas showing increased K-ras 4B expression, increased proliferation, decreased apoptosis, and activation of MapKinase and Akt pathways, in the absence of K-ras mutations.
  • Therefore, K-ras 4A expression had a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation, explaining the selective advantage of the altered K-ras 4A : 4B isoform ratio found in human colorectal cancer.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Genes, Tumor Suppressor. Genes, ras. Proto-Oncogene Proteins p21(ras) / genetics

  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087880.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


96. Woerner SM, Kloor M, Mueller A, Rueschoff J, Friedrichs N, Buettner R, Buzello M, Kienle P, Knaebel HP, Kunstmann E, Pagenstecher C, Schackert HK, Möslein G, Vogelsang H, von Knebel Doeberitz M, Gebert JF, German HNPCC Consortium: Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene; 2005 Apr 7;24(15):2525-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability of selective target genes in HNPCC-associated colon adenomas.
  • Instability at coding microsatellites (cMS) in specific target genes causes frameshift mutations and functional inactivation of affected proteins, thereby providing a selective growth advantage to MMR deficient cells.
  • In this study, we examined 30 HNPCC-associated MSI-H colorectal adenomas of different grades of dysplasia for frameshift mutations in 26 cMS-bearing genes, which, according to our previous model, represent Selective Target genes of MSI.
  • About 30% (8/26) of these genes showed a high mutation frequency (> or =50%) in colorectal adenomas, similar to the frequencies reported for colorectal carcinomas.
  • Mutations in one gene (PTHL3) occurred significantly less frequently in MSI adenomas compared to published mutation rates in MSI carcinomas (36.0 vs 85.7%, P=0.023).
  • [MeSH-major] Adenoma / genetics. Adenoma / physiopathology. Cell Transformation, Neoplastic / genetics. Chromosomal Instability. Colonic Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Microsatellite Repeats

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735733.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


97. Yu CC, Lau C, O'Donoghue G, Mirkovic J, McGee S, Galindo L, Elackattu A, Stier E, Grillone G, Badizadegan K, Dasari RR, Feld MS: Quantitative spectroscopic imaging for non-invasive early cancer detection. Opt Express; 2008 Sep 29;16(20):16227-39
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative spectroscopic imaging for non-invasive early cancer detection.
  • We validate its diagnostic ability on a resected colon adenoma, and demonstrate feasibility of in vivo imaging in the oral cavity.

  • MedlinePlus Health Information. consumer health - Benign Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Obstet Gynecol. 1999 Mar;93(3):462-70 [10075001.001]
  • [Cites] IEEE Eng Med Biol Mag. 2004 Sep-Oct;23(5):40-9 [15565798.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024031 [15910104.001]
  • [Cites] Photochem Photobiol. 2000 Jul;72(1):103-13 [10911734.001]
  • [Cites] Lasers Surg Med. 2005 Jun;36(5):356-64 [15856507.001]
  • [Cites] Chest. 2006 Apr;129(4):995-1001 [16608949.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] J Biomed Opt. 2006 May-Jun;11(3):34009 [16822059.001]
  • [Cites] Appl Opt. 2007 Apr 1;46(10):1896-910 [17356636.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034015 [17614723.001]
  • [Cites] Oral Oncol. 2008 Jan;44(1):65-71 [17350324.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1620-9 [11375944.001]
  • [Cites] Am J Obstet Gynecol. 2002 Mar;186(3):374-82 [11904594.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Mar;26(3):220-4 [11981461.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1681-92 [12655525.001]
  • [Cites] Technol Cancer Res Treat. 2003 Dec;2(6):505-14 [14640762.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Histopathology. 1990 Apr;16(4):371-6 [2361652.001]
  • [Cites] Dig Dis Sci. 1995 Jun;40(6):1261-8 [7781444.001]
  • [Cites] Lasers Surg Med. 1995;17(4):350-7 [8684237.001]
  • [Cites] Br J Obstet Gynaecol. 1998 Feb;105(2):206-10 [9501788.001]
  • [Cites] Ann N Y Acad Sci. 1998 Feb 9;838:116-22 [9511800.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Nov;124(11):1251-8 [9821929.001]
  • [Cites] Science. 1962 Aug 17;137(3529):499-508 [13878016.001]
  • (PMID = 18825262.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097966-05; United States / NCRR NIH HHS / RR / P41 RR002594-210122; United States / NCRR NIH HHS / RR / P41 RR002594-235015; United States / NCRR NIH HHS / RR / RR002594-235014; United States / NCI NIH HHS / CA / CA097966-03; United States / NCRR NIH HHS / RR / P41 RR002594-200085; United States / NCRR NIH HHS / RR / P41 RR002594-210121; United States / NCI NIH HHS / CA / R01 CA097966-03; United States / NCRR NIH HHS / RR / RR002594-210122; United States / NCI NIH HHS / CA / R01-CA97966; United States / NCRR NIH HHS / RR / P41 RR002594-226948; United States / NCI NIH HHS / CA / CA097966-02; United States / NCRR NIH HHS / RR / RR002594-226948; United States / NCRR NIH HHS / RR / RR002594-200085; United States / NCI NIH HHS / CA / R01 CA097966-02; United States / NCI NIH HHS / CA / R01 CA097966-05; United States / NCRR NIH HHS / RR / P41-RR02594; United States / NCRR NIH HHS / RR / P41 RR002594-190084; United States / NCI NIH HHS / CA / R01 CA097966; United States / NCI NIH HHS / CA / CA097966-01; United States / NCRR NIH HHS / RR / P41 RR002594; United States / NCRR NIH HHS / RR / P41 RR002594-226947; United States / NCI NIH HHS / CA / R01 CA097966-01; United States / NCRR NIH HHS / RR / RR002594-190084; United States / NCRR NIH HHS / RR / RR002594-190085; United States / NCI NIH HHS / CA / CA097966-04; United States / NCRR NIH HHS / RR / RR002594-235015; United States / NCRR NIH HHS / RR / P41 RR002594-190085; United States / NCI NIH HHS / CA / R01 CA097966-04; United States / NCRR NIH HHS / RR / P41 RR002594-235014; United States / NCRR NIH HHS / RR / RR002594-210121; United States / NCRR NIH HHS / RR / RR002594-226947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78689; NLM/ PMC2606148
  •  go-up   go-down


98. M Bustamante-Balén, Bernet L, Cano R, Morell L, López A: Assessing the reproducibility of the microscopic diagnosis of sessile serrated adenoma of the colon. Rev Esp Enferm Dig; 2009 Apr;101(4):258-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the reproducibility of the microscopic diagnosis of sessile serrated adenoma of the colon.
  • INTRODUCTION: sessile serrated adenoma (SSA) is a recently described lesion that may be related to the development of up to 15% of colorectal cancers (CRCs).
  • MATERIAL AND METHODS: concordance between two pathologists in the diagnosis of serrated lesions of the colon was studied for 195 lesions (187 hyperplastic polyps and 7 serrated adenomas).
  • Possible diagnoses were: SSA, traditional serrated adenoma (TSA), hyperplastic polyp (HP), serrated polyp, tubular adenoma, or mixed lesions.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19492901.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


99. Schmitz KJ, Hey S, Schinwald A, Wohlschlaeger J, Baba HA, Worm K, Schmid KW: Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon. Virchows Arch; 2009 Jul;455(1):49-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon.
  • This study was designed to analyse the potential diagnostic value of miR-181b and miR-21 for discriminating hyperplastic polyps (HP) from sessile serrated adenomas (SSA) without cytologic dysplasia.
  • Using real-time polymerase chain reaction expression levels of miR-181b and miR-21 in 18 HPs, 19 SSAs without cytologic dysplasia and 20 normal colonic mucosal specimens were examined.
  • A differential expression of miR-181b and miR-21 was found in HPs, SSAs, and normal colonic mucosa with highest expression levels in SSAs.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Colonic Polyps / genetics. MicroRNAs / analysis

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547998.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MIRN21 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


100. Siddiqui AA, Patel A, Huerta S: Determinants of compliance with colonoscopy in patients with adenomatous colon polyps in a veteran population. Aliment Pharmacol Ther; 2006 Dec;24(11-12):1623-30
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of compliance with colonoscopy in patients with adenomatous colon polyps in a veteran population.
  • AIM: To determine factors affecting compliance of a follow-up colonoscopy in patients with previously diagnosed adenomatous colon polyps.
  • METHODS: A retrospective review was performed on patients with adenomatous polyps excised between January and December 1998.
  • RESULTS: One hundred and nineteen patients with adenomatous colon polyps were identified.
  • In a univariate analysis, greater number of polyps (P = 0.04), NSAID use (P = 0.02), statin use (P = 0.005), first-degree relatives with colon cancer (P = 0.05) and compliance with out-patient clinic follow-up (P < 0.001) were significantly associated with patient compliance.
  • Multivariate analysis revealed statin use (P = 0.05), first-degree relatives with colon cancer (P = 0.06) and compliance with out-patient clinic follow-up (P < 0.001) were independent predictors of compliance.
  • CONCLUSIONS: History of statin use and family history of colon cancer are good predictors of compliance.
  • Strong efforts should be directed at improving patient education about colon cancer by the physician and facilitating patient compliance.
  • [MeSH-major] Adenomatous Polyps / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Colonoscopy. Patient Compliance

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206950.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement